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57 ABSTRACT 
Texaphyrins are provided for use as radiation sensitizers. 
Advantageous properties of texaphyrins for use as a radia 
tion sensitizer include: i) a low redox potential which allows 
radiation-induced hydrated electrons to flow to texaphyrin 
rather than neutralizing hydroxyl radicals, allowing 
hydroxyl radicals to cause cellular damage, ii) a relatively 
stable texaphyrin radical that reacts readily to covalently 
modify neighboring molecules causing further cellular 
damage, iii) intrinsic biolocalization, and iv) indifference to 
the presence or absence of O. These properties allow 
texaphyrins to be particularly effective for treating the 
hypoxic areas of solid neoplasms. Methods of treatment for 
an individual having a neoplasm or atheroma include the use 
of a texaphyrin as a radiation sensitizer and as an agent for 
photodynamic tumor therapy, or the use of a texaphyrin for 
internal and for external ionizing radiation. Novel texaphy 
rins are provided. 
26 Claims, 14 Drawing Sheets 
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METAL COMPLEXES OF TEXAPHYRNS 
This application is a continuation of application Ser. No. 
08/437.968, filed May 10, 1995, now U.S. Pat. No. 5,622, 
946 and a continuation-in-part of application Ser. No. 
08/679,162, filed Jul. 10, 1996. Ser. No. 08/437,968 is a 
continuation of International application Ser. No. PCT/ 
US94/11491, filed Oct. 12, 1994 and designating the United 
States of America, which international application is a 
continuation-in-part of application Ser. No. 08/135,118, filed 
Oct. 12, 1993 and now U.S. Pat. No. 5457,183, which is a 
continuation-in-part of application Ser. No. 08/075,123 filed 
Jun. 9, 1993, now abandoned, which is a continuation-in 
part of application Ser. No. 07/822,964, filed Jan. 21, 1992 
and now U.S. Pat. No. 5.252,720. Ser. No. 08/679,162 is a 
continuation of application Ser. No. 08/098,514, filed Jul. 
28, 1993, now U.S. Pat. No. 5,569,759, which is a division 
of application Ser. No. 07/822,964, filed Jan. 21, 1992 and 
now U.S. Pat. No. 5.252,720. The entire disclosures of the 
above applications and patents are incorporated herein by 
reference. 
FIELD OF THE INVENTION 
The present invention relates to the field of radiation 
sensitizers and the use of texaphyrins for radiation sensiti 
zation and other conditions for which X-ray radiation has 
proven to be therapeutic. 
BACKGROUND OF THE INVENTION 
A radiation sensitizer is an agent used to enhance the 
effect of radiation therapy. In delivering potentially curative 
doses of radiation, it is necessary to balance the need for 
local tumor control with the potential for damage to sur 
rounding normal tissues by the delivered dose of radiation 
(Bush et al., 1978). It is therefore desirable to use the lowest 
radiation dose consistent with local control. One way to 
achieve this would be to utilize a radiation sensitizing agent 
to enhance cytotoxicity of delivered radiation to the tumor. 
Radiation causes cell death by damaging critical targets 
within the cell, most commonly chromosomal DNA 
(Hendrickson and Withers, 1991). Radiation therapy relies 
on two types of ionizing radiation: (1) directly ionizing 
Subatomic particle radiation, such as alpha particles and beta 
particles (electrons), neutrons, protons, mesons, heavy 
charged ions, etc., and (2) indirectly ionizing electromag 
netic radiation, which exists as a family of waves of varying 
frequency including high frequency x-rays or gamma rays. 
However, of the two, electromagnetic radiation is more 
commonly used in radiation therapy today. In tissue, elec 
tromagnetic radiation in the form of x-rays or gamma rays 
can interact with molecules (especially water) causing the 
ejection of high-energy electrons. The electrons can break 
the sugar phosphate bonds in DNA directly (direct action) or 
the process of electron ejection can ultimately produce free 
(uncharged) radicals that can also break the chemical (sugar 
phosphate) bonds in DNA (indirect action). The damage 
caused through the indirect mechanism is more significant 
(Hendrickson and Withers, 1991; Mulcahy et al., 1993; 
Rubin and Siemann, 1993; Chapman et al., 1974). These 
damaging effects are mediated by the radiation products of 
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Radiation damage is produced primarily by the hydroxyl 
radical, HO, an oxidizing radical. This radical is extremely 
reactive and short lived. It causes damage primarily in the 
vicinity in which it is generated (+4 nm). If it comes into 
contact with a hydrated electron (e), it is deactivated by 
conversion to a hydroxide ion (OH). Hydrated electrons are 
strong reducing species and highly energetic. They are very 
mobile by comparison to the hydroxyl radical. can travel 
distances quickly, and through direct action can damage 
DNA. However, as mentioned above, they also deactivate 
hydroxyl radicals readily. Agents with strong electron 
affinity, by virtue of "soaking up" solvated electrons, prevent 
them from neutralizing hydroxyl radicals and thereby allow 
hydroxyl radicals to exert their effect (Adams and Dewey, 
1963). Oxygen and other compounds with strong electron 
affinity would thus be expected to act as radiation sensitiz 
CTS, 
The biological responses to radiation-induced cell injury 
may be modulated by various endogenous and exogenous 
compounds, and failure of radiation therapy to achieve local 
cure is multifactorial. For instance, sulfhydryl compounds, 
including cysteine, dithiothreitol, and cysteamine have been 
shown to protect living cells against the lethal effects of 
ionizing radiation by acting as reducing agents (Rubin and 
Siemann. 1993) and facilitating the recombination of the ion 
pairs. It also has been observed that depletion of cellular 
sulfhydryl compounds can result in radiosensitization. 
One of the major factors mediating failure of radiation 
therapy, or radioresistance, is hypoxia. Hypoxic cells in solid 
tumors have been observed to be 2.5-3 times more resistant 
to the damaging effect of ionizing radiation (Tannock, 1972; 
Watson et al., 1978; both cited in Brown, 1984). Local 
cure/control rates of a tumor can be increased with an 
effective increase in the radiation dose; however, such an 
increase would damage adjacent, fully-oxygenated normal 
tissues to a greater degree than the tumor cells (Shenoy and 
Singh. 1992). Specific modification of tumor radiosensitiv 
ity has been pursued through alteration of the tumor oxy 
genation state achieved by fractionation of the radiation dose 
and by the attempted use of chemical radiation sensitizers 
(Wang, 1988; Shenoy and Singh, 1992). 
Fractionation results in reduced radiation effects in nor 
mal tissue as compared with a single acute dose due to cell 
repopulation and repair of sublethal damage between dose 
fractions. In malignant tumor tissues, radiosensitive oxygen 
ated cells are destroyed with a subsequent reduction in 
tumor size. Subsequently, radioresistant hypoxic cells dis 
tant from functional vasculature become reoxygenated and 
therefore more radiosensitive. Reassortment of cells within 
the cell cycle also occurs and renders the cancer cells more 
radiosensitive. This differential response between tumor and 
normal cells may allow dose fractionation to be more 
tumoricidal than an equal single radiation dose. 
Various types of electron-affinic reagents are known to 
promote radiosensitization of cells with diminished oxygen 
supply (Shenoy and Singh, 1992). However, few of these 
show activity at non-toxic doses in vivo. For instance, 
clinical trials with one of the better known agents. 
misonidazole, demonstrated that it is highly effective against 
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a number of animal and human tumors (Thomlinson et al., 
1976; Ash et al., 1979; Denekamp et al., 1980; all cited in 
Brown. 1984). However, the neurological side-effects 
severely limit its clinical usefulness (Kallman, 1972; Dische 
et al., 1977; Urtasun et al., 1978: Waserman et al., 1979; all 
cited in Brown, 1984; and Dische et al., 1979). Approaches 
aimed at improving the therapeutic index of nitroimidazoles 
have included lowering the lipophilicity so as to restrict 
nervous tissue penetration and toxicity, and accelerating 
renal clearance (Beard et al., 1993). Clinical trials with these 
second-generation analogs of misonidazole have been 
reported or are on-going (Roberts et al., 1984; Coleman et 
al., 1984; Saunders et al., 1984; Coleman et al., 1986; 
Horwich et al., 1986; Newman et al., 1986; Dische et al., 
1986; Coleman et al., 1987; Newman et al., 1988; Workman 
et al., 1989). However, the approaches have yet to produce 
highly effective hypoxic cell sensitizers. 
Halogenated pyrimidines also have been studied as radia 
tion sensitizers. These agents modify the radiosensitivity of 
cells through structural alteration of the DNA, making the 
DNA more susceptible to radiation inactivation. However, 
the drugs must be present in the cells for extended periods 
since the degree of radiosensitization is directly related to 
the degree of thymidine substitution. In addition, the agents 
may undergo rapid hepatic degradation and dehalogenation 
(Shenoy and Singh. 1992). The main limiting factor from 
prolonged use of halogenated pyrimidines has become bone 
marrow toxicity (Kinsella et al., 1984a; Kinsella et al., 
1984b; Kinsella et al., 1985; cited in Shenoy and Singh, 
1992). 
Hypoxic cell sensitizers fall within the broad category of 
chemical modifiers of cancer treatment. Chemical modifiers 
are usually not cytotoxic by themselves but modify or 
enhance the tissue response to standard radiation therapy. 
The ultimate utility of a radiotherapy or chemotherapy 
modifier depends upon its ability to alter the therapeutic 
index. 
Texaphyrins have been described in U.S. Pat. Nos. 4.935, 
498,5162.509, 5.252,720, 5.292414, 5.252,142, 5.457,183 
and 5.256,399; U.S. applications Ser. No. 08/196964, 
08/294344, and 08/227.370; and PCT/US94/06284, all of 
which are incorporated by reference herein. The photophysi 
cal properties of various texaphyrins are reported in U.S. 
Pat. No. 5.252,720, incorporated by reference herein, and 
include strong low energy optical absorptions in the 
690-880 nm spectral range, a high triplet quantum yield and 
efficient production of singlet oxygen. U.S. Pat. No. 5.252. 
720 also describes photosensitized inactivation of enveloped 
viruses and magnetic resonance imaging (MRI) of atheroma, 
liver, kidney and tumor using various substituted texaphyrin 
metal complexes. Altering the polarity and electrical charges 
of side groups of these macrocycles alters the degree, rate, 
and site(s) of binding to free enveloped viruses such as 
HIV-1 and to virally-infected peripheral mononuclear cells, 
thus modulating photosensitizer take-up and photosensitiza 
tion of leukemia or lymphoma cells contaminating bone 
marrow. Powerful techniques include the use of these texa 
phyrins in magnetic resonance imaging followed by 
photodynamic tumor therapy in the treatment of atheroma, 
and benign and malignant tumors. 
The present invention provides texaphyrins for radiation 
sensitization. Texaphyrins enhance radiation damage and 
overcome many of the drawbacks of prior art radiation 
sensitizers. 
SUMMARY OF THE INVENTION 
The present invention provides texaphyrins as radiation 












of radiation therapy for a host harboring a neoplasm or 
atheroma including the steps of: i) administering to the host 
a texaphyrin, and ii) administering ionizing radiation to the 
texaphyrin in proximity to the neoplasm or atheroma. Texa 
phyrins are demonstrated herein to have radiation sensitiza 
tion properties; they enhance cytotoxicity from ionizing 
radiation in the vicinity of the texaphyrin as compared to 
control experiments. Ionizing radiation includes, but is not 
limited to, X-rays, internal and external gamma emitting 
radioisotopes, and ionizing particles. 
A texaphyrin is an aromatic pentadentate macrocyclic 
"expanded porphyrin." Texaphyrins, water-soluble 
texaphyrins, and methods of preparation are known in the art 
and are disclosed in the U.S. patents and patent applications 
previously incorporated by reference herein. Possibly due to 
its inherent lipophilicity, texaphyrin exhibits greater biolo 
calization in neoplastic tissue and atheroma relative to 
non-neoplastic tissue and non-atheromatous plaque. A neo 
plasm may be a benign or a malignant tumor. 
The above-described method may include the further step 
of determining localization sites in the host by reference to 
a detectable texaphyrin. "By reference to a detectable texa 
phyrin" as used herein means that the location may be found 
by localization means such as fluorescent spectroscopy. 
especially when the texaphyrin is non-metallated or is 
complexed with a diamagnetic metal; magnetic resonance 
imaging when the texaphyrin contains a metal that is para 
magnetic; gamma camera body scanning when the metal is 
gamma emitting; or by using diagnostic X-rays, especially 
mono-or polychromatic X-rays with energy around the K 
electrons of metals bound to texaphyrin. Gamma emitting 
metals for radioimmunodiagnostics are described in U.S. 
Pat. No. 5.252,720, incorporated by reference herein. A 
preferred gamma emitting metal is 'In(III) 
In each of these methods, the texaphyrin may be com 
plexed with a metal, although the metal is not central to the 
radiosensitization properties of the texaphyrins. The metal 
can be important to the stability of the texaphyrin complex. 
The ionizing radiation is from an external source unless the 
metal is a radioactive metal. In that case, the ionizing 
radiation is from the radioactive metal and could be in 
combination with radiation from an external source. 
A further embodiment of the present invention is the use 
of texaphyrins for a combined method of radiation sensiti 
zation and photodynamic therapy in the treatment of a 
neoplasm or atheroma. This method comprises the admin 
istration of a photosensitive texaphyrin and delivering ion 
izing radiation and light in proximity to the neoplasm or 
atheroma. The photosensitive texaphyrin is a metal-free 
texaphyrin or a texaphyrin-diamagnetic metal complex. 
Alternatively, a first texaphyrin may be administered that is 
detectable so that localization may be accomplished by 
reference to the detectable texaphyrin. A second photosen 
sitive texaphyrin may be administered with the first or 
afterwards so that both radiation sensitization and photody 
namic therapy may be carried out. The method comprises 
the steps of i) administering to the host as a first agent a 
detectable texaphyrin. ii) determining localization sites in 
the host by reference to the detectable texaphyrin. iii) 
administering to the host as a second agent a photosensitive 
texaphyrin, and iv) administering ionizing radiation and 
photoirradiation in proximity to the neoplasm or atheroma. 
The second agent has essentially identical biolocalization 
property as the first agent and exhibits the ability to generate 
oxygen upon exposure to light. The photodynamic effect 
may be derived from anaerobic electron transfer processes 
or from aerobic, oxygen-based processes. Cytotoxic oxygen 
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products may be singlet oxygen, hydroxyl radicals. 
superoxide, or hydroperoxyl radicals. The photosenstivie 
texaphyrin may be a diamagnetic metal complex or a 
metal-free species. Presently preferred diamagnetic metal 
texaphyrin complexes are the Lu(III). La(III) or In(III) 
complex of B2T2 (see U.S. Pat. No. 5.252,720, incorporated 
herein by reference) or of T2BET (see Example 1, this 
application). 
Texaphyrin metal complexes possess inherent biolocal 
ization specificity as described in the '720 patent, localizing 
in lipid rich regions such as, for example, liver, kidney, 
tumor and atheroma. "Exhibiting greater biolocalization” in 
neoplastic tissue and atheroma as compared to non 
neoplastic tissue and non-atheromatous plaque means hav 
ing an inherently greater affinity for neoplastic tissue and 
atheroma relative to non-neoplastic tissue and non 
atheromatous plaque. "Essentially identical biolocalization 
property" means the second agent is a texaphyrin derivative 
having about the same selective targeting characteristics in 
tissue as demonstrated by the first agent. The first agent and 
the second agent may be the same texaphyrin. Importantly, 
hydroxylated texaphyrins have a lipid-water distribution 
coefficient that is optimal for localization to lipophilic 
regions, yet sufficiently water-soluble to allow ease of 
handling. 










wherein M is H. a divalent metal cation or a trivalent metal 
cation. A preferred divalent metal cation is selected from the 
group consisting of Ca(II), Mn(DI), Co(II), Ni(II), Zn(II), 
CdCII), Hg(II), Fe(II). Sm(II) and UO(II). A preferred 
trivalent metal cation is selected from the group consisting 











In(III), Pr(III). NdIII). Sm(III). Eu(III), Gd(III), Tb(III), 
Dy(III), Er(III), Tm(III), Yb(III), Lu(III). La(III), and U(III). 
In this texaphyrin structure. R-R and R-R are inde 
pendently hydrogen, halide other than iodide, hydroxyl, 
alkyl, aryl, haloalkyl other than iodoalkyl, nitro, formyl, 
acyl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, 
aminoalkyl, oxyaminoalkyl, carboxy, carboxyalkyl. 
carboxyamidealkyl, a site-directing molecule or a couple to 
a site-directing molecule. Rs and Ro are independently 
hydrogen, alkyl, aryl, hydroxyalkyl oxyalkyl, 
oxyhydroxyalkyl, a mino alkyl, oxyamino alkyl, 
carboxyalkyl, carboxyamidealkyl or a couple to a site 
directing molecule; and R is alkyl, alkenyl, oxyalkyl or 
hydroxyalkyl having up to about 3 carbon atoms and having 
rotational flexibility around a first-bound carbon atom. In the 
above described texaphyrin; where R and Rare other than 
hydrogen, then Rs and Ro are hydrogen or methyl and 
where R and Ro are other than hydrogen, then R and R. 
are hydrogen, hydroxyl, or halide other than iodide. N is 0. 
1 or 2. 
In the above-described texaphyrins, the halide other than 
iodide may be fluoride, chloride or bromide. The alkyl, aryl, 
hydroxyalkyl, oxyalkyl oxyhydroxyalkyl, saccharide. 
carboxyalkyl, carboxyamidealkyl, or site-directing molecule 
is covalently bonded to the texaphyrin via a carbon-carbon 
or a carbon-oxygen bond. The aryl may be a phenyl sub 
stituent or a phenyl having a nitro, carboxy, sulfonic acid. 
hydroxy, oxyalkyl or halide other than iodide substituent. In 
this case, the substituent on the phenyl group may be added 
in a synthetic step after the condensation step which forms 
the macrocycle. 
In one embodiment of the present invention, the texaphy 
rin is coupled to site-directing molecules to form conjugates 
for targeted in vivo delivery. "Specificity for targeted sites" 
means that upon contacting the texaphyrin conjugate with 
the targeted site, for example, under physiological condi 
tions of ionic strength, temperature, pH and the like, specific 
binding will occur. The interaction may occur due to specific 
electrostatic, hydrophobic, entropic or other interaction of 
certain residues of the conjugate with specific residues of the 
target to form a stable complex under conditions effective to 
promote the interaction. 
Exemplary site-directing molecules contemplated in the 
present invention include but are not limited to: 
oligodeoxyribonucleotides. oligoribonucleotide analogs; 
polyamides including peptides having affinity for a biologi 
cal receptor and proteins such as antibodies, low density 
lipoproteins, the APO protein of lipoprotein; steroids and 
steroid derivatives; hormones such as estradiol, or hista 
mine; hormone mimics such as morphine; and further mac 
rocycles such as sapphyrins and rubyrins. An oligonucle 
otide may be derivatized at the base, the sugar, the ends of 
the chain, or at the phosphate groups of the backbone to 
promote in vivo stability. Modification of the phosphate 
groups is preferred in one embodiment of the invention since 
phosphate linkages are sensitive to nuclease activity. Pre 
ferred derivatives are methylphosphonates. 
phosphotriesters, phosphorothioates, and phosphoramidates 
and the like. Additionally, phosphate linkages may be com 
pletely substituted with non-phosphate linkages such as 
amide linkages. Appendages to the ends of the oligonucle 
otide chain also provide exonuclease resistance. Sugar 
modifications may include alkyl groups attached to an 
oxygen of a ribose moiety in a ribonucleotide. In particular, 
the alkyl group is preferably a methyl group and the methyl 
group is attached to the 2 oxygen of the ribose. Other alkyl 
groups may be ethyl or propyl. It is understood that the terms 




both naturally-occurring and synthetic nucleotides, poly 
and oligonucleotides and to analogs and derivatives thereof. 
The term "texaphyrin-oligonucleotide conjugate" means 
that an oligonucleotide is attached to the texaphyrin in a 5' 
or 3' linkage or both types of linkages to allow the texaphy 
rin to be an internal residue in the conjugate. The oligo 
nucleotide or other site-directing molecule may be attached 
either directly to the texaphyrin via a linker, or a couple of 
variable length. During treatment, for example, the texaphy 
rin portion of a texaphyrin metal complex-oligonucleotide 
conjugate is envisioned as being placed in the vicinity of the 
targeted tissue upon binding of the oligonucleotide to its 
complementary DNA. 
A couple may be described as a linker, i.e. the covalent 
product formed by reaction of a reactive group designed to 
attach covalently another molecule at a distance from the 
texaphyrin macrocycle. Exemplary linkers or couples are 
amides. amine, thioether, ether, orphosphate covalent bonds 
as described in the examples for attachment of oligonucle 
otides. In most preferred embodiments, oligonucleotides and 
other site-directing molecules are covalently bonded to the 
texaphyrin via a carbon-nitrogen, carbon-sulfur, or a carbon 
oxygen bond. The oligonucleotide, the antibody, the hor 
mone or the sapphyrin may have binding specificity for 
localization to a treatment site and the biological receptor 
may be localized to a treatment site. 
The term "a peptide having affinity for a biological 
receptor” means that upon contacting the peptide with the 
biological receptor, for example, under appropriate condi 
tions of ionic strength, temperature, pH and the like, specific 
binding will occur. The interaction may occur due to specific 
electrostatic, hydrophobic, entropic or other interaction of 
certain amino acid or glycolytic residues of the peptide with 
specific amino acid or glycolytic residues of the receptor to 
form a stable complex under the conditions effective to 
promote the interaction. The interaction may alter the three 
dimensional conformation and the function or activity of 
either or both the peptide and the receptor involved in the 
interaction. A peptide having affinity for a biological recep 
tor may include an endorphin, an enkephalin, a growth 
factor, e.g. epidermal growth factor, poly-L-lysine, a 
hormone, a peptide region of a protein and the like. A 
hormone may be estradiol. for example. 
While the above structures A and B are presently 
preferred, the invention is not limited thereto and any 
texaphyrin or texaphyrin metal complex may be used in the 
radiation sensitization methods of the present invention. 
The method of radiation therapy using texaphyrins pro 
vided herein incorporates a number of strategies to optimize 
specificity of treatment. The first is the inherent biolocal 
ization of texaphyrins to lipid rich tissue, the second is the 
ability to conjugate site-directing molecules to the periphery 
of the texaphyrin and the third is the ability to position 
radiation to a particular site. For example, a complementary 
oligonucleotide is designed to base pair with the targeted 
substrate and the positioning of incident radiation, either by 
manual or mechanical means, would be particularly advan 
tageous when cytotoxicity is to be effected at a particular 
biological locus, such as, for instance, a deep-seated tumor 
site. In this instance, photodynamic therapy may be advan 
tageously combined with radiation therapy for treatment. 
The fact that the texaphyrins absorb light at wavelengths 
where bodily tissues are relatively transparent (700-900 nm) 
is particularly advantageous. This procedure allows for the 
effective implementation of radiation- and light-based oli 
gonucleotide strategies at loci deep within the body with 












other tissues where the texaphyrins or the texaphyrin con 
jugates are not localized. 
In the above-described texaphyrin structure A, N will 
typically be an integer less than or equal to 2. In the context 
of the basic macrocycle with a divalent or trivalent metal 
cation. N is 1 or 2; however, one skilled in the art in light of 
the present disclosure would realize that the value of N 
would be altered due to charges present on substituents 
R-Ro and charges present on the covalently bound site 
directing molecule, for example, charges of the phosphate 
groups on an oligonucleotide. 
Alkyl means an alkyl group, straight or branched chain, of 
1 to 10 carbon atoms. Alkenyl means an alkenyl group, 
straight or branched chain, of 1 to 10 carbon atoms and 
having one or two double bonds. Hydroxyalkyl means an 
alkyl group having from 1 to 20 hydroxyl groups attached. 
Alkoxy means an alkyl group attached to an oxygen. 
Hydroxyalkoxy means an alkyl group having ether linkages, 
and hydroxyl or substituted hydroxyl groups or the like. 
Saccharide includes oxidized, reduced or substituted sac 
charide; hexoses such as D-glucose, D-mannose or 
D-galactose; pentoses such as D-ribose or D-arabinose; 
ketoses such as D-ribulose or D-fructose; disaccharides such 
as sucrose, lactose, or maltose; derivatives such as acetals, 
amines, and phosphorylated sugars; oligosaccharides, as 
well as open chain forms of various sugars, and the like. 
Examples of amine-derivatized sugars are galactosamine. 
glucosamine. sialic acid and D-glucamine derivatives such 
as 1-amino-1-deoxysorbitol. Aminoalkyl means alkyl hav 
ing an amine group. Oxyaminoalkyl means an alkyl group 
having an ether linkage and having an amine group. Car 
boxyamidealkyl means an alkyl group with secondary or 
tertiary amide linkages or the like. Carboxyalkyl means an 
alkyl group having one or more carboxyl groups, or one or 
more ester linkages. 
For the above-described texaphyrin structures, hydroxy 
alkoxy may be alkyl having independently hydroxy sub 
stituents and ether branches or may be CH-12. 
OO, or OC-H2--1-2OO, where n is a positive 
integer from 1 to 10, x is zero or a positive integer less than 
or equal to n, and y is zero or a positive integer less than or 
equal to ((2n+1)-2x). The hydroxyalkoxy or saccharide may 
be C.H. (21 OR OCH2--1-OR or (CH2), 
COR where n is a positive integer from 1 to 10, y is zero 
or a positive integer less than ((2n+1)-q), q is zero or a 
positive integer less than or equal to 2n+1, and R is 
independently H, alkyl, hydroxyalkyl, saccharide, C 
Hcc2n+1)-2 wow0. O2CCon-whic2n+1)-2-O-O- O 
N(R)OCCH12OO. In this case, m is a posi 
tive integer from 1 to 10, w is zero or a positive integer less 
than or equal to m, Z is zero or a positive integer less than 
or equal to ((2m+1)-2w), and R is H. alkyl, hydroxyalkyl, 
or C. Hom--OR, where m is a positive integer from 1 
to 10, Z is zero or a positive integer less than ((2m+1)-r), r 
is Zero or a positive integer less than or equal to 2m+1, and 
R is independently H. alkyl, hydroxyalkyl, or saccharide. 
Carboxyamidealkyl may be alkyl having secondary or 
tertiary amide linkages or (CH2)CONHR'. O(CH), 
CONHR'. (CH),CON(R), or O(CH),CON(R), where n 
is a positive integer from 1 to 10. and R is independently 
H. alkyl hydroxyalkyl, saccharide, CH2-2 
O.O. O2CCon-w)Hoc2n+1)-2O.O. N(R)OCC 
H22O.O. or a site-directing molecule. In this case, 
m is a positive integer from 1 to 10, w is zero or a positive 
integer less than or equal to m, Z is zero or a positive integer 
less than or equal to ((2m+1)-2w), and R is H. alkyl, 
hydroxyalkyl, or C.H.O.R. In this case, m is a 
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positive integer from 1 to 10, Z is zero or a positive integer 
less than ((2m+1)-r), r is zero or a positive integer less than 
or equal to 2m+1, and R is independently H. alkyl, 
hydroxyalkyl, or saccharide. In a preferred embodiment, R 
is an oligonucleotide. 
Carboxyalkyl may be alkyl having a carboxyl substituted 
ether, an amide substituted ether or a tertiary amide removed 
from an ether or CH2O,R or OCH2O.R. 
where n is a positive integer from 1 to 10; y is zero or a 
positive integer less than ((2n+1)-q), q is zero or a positive 
integer less than or equal to 2n+1, and R is (CH2)CO.R. 
(CH),CONHR'. (CH2)CONCR) or a site-directing mol 
ecule. In this case, n is a positive integer from 1 to 10, R 
is independently H. alkyl, hydroxyalkyl, saccharide, C. 
H(2m+1-2O.O. O2CC-H (2m+1)-2OO. O N(R) 
OCCH2O.O. In this case, m is a positive 
integer from 1 to 10, w is zero or a positive integer less than 
or equal to m, Z is zero or a positive integer less than or equal 
to (2m+1)-2w), and R is H. alkyl, hydroxyalkyl, or C. 
Hon; OR, In this case, m is a positive integer from 1 
to 10, z is zero or a positive integer less than ((2m+1)-r), r 
is zero or a positive integer less than or equal to 2m+1, and 
R is independently H, alkyl, hydroxyalkyl, or saccharide. In 
a preferred embodiment, R is an oligonucleotide. 
A presently preferred embodiment of the present inven 
tion is a method of radiation therapy for a host harboring a 
neoplasm or atheroma comprising the steps of i) adminis 
tering to the host a pharmaceutically effective amount of the 
Gd complex of a texaphyrin, and ii) administering ionizing 
radiation to the texaphyrin in proximity to the neoplasm or 
atheroma. A more preferred embodiment of the invention is 
the above method where the texaphyrin is the Gd complex 
of T2B2, 4,5-diethyl-10.23-dimethyl-9.24-bis(3- 
hydroxypropyl)-16,17-(3-hydroxypropyloxy)-13.20.25,26, 
27-pentaazapentacyclo[20.2.1.1.1'.0'']heptacosa-1, 
3.5.7.9.11(27). 12.14(19). 15.17.20.22(25).23-tridecaene, or 
the Gd complex of T2BET, 4.5-diethyl-1023-dimethyl-9, 
24-bis (3-hydroxypropyl)-16. 17-bis(2- 2-(2- 
methoxyethoxy)ethoxyethoxy)-pentaazapentacyclo 
(20.2.1.1.1.0-heptacosa-1,3,5,7,9.11(27), 12.14. 
16.18.20.22(25).23-tridecaene. A particularly preferred 
embodiment is where the texaphyrin is the Gd complex of 
T2BET. 
In presently preferred texaphyrins. R is hydroxyalkyl and 
R. R. and R are alkyl. Alternatively, R may be a site 
directed molecule or a couple to a site-directed molecule, 
preferably an oligonucleotide or a couple to an oligonucle 
otide. In a further preferred texaphyrin, R is (CH2) 
CHOH. R. and R are CHCH. R. is CH and R, and Rs. 
are OCHCHCH-OH. Alternatively, R is a site-directed 
molecule or a couple thereto, preferably an oligonucleotide 
or a couple thereto, more preferably O(CH2)CO 
oligonucleotide where n is 1-7 and preferably 1-3; and R. 
is H. In a further presently preferred embodiment, R is 
(CH2)CH2OH. R. and R are CHCH. R. is CH R and 
Rs are O(CHCHO)CHCHOCH, alternatively, R is a 
site-directed molecule or a couple thereto, preferably an 
oligonucleotide or a couple thereto, more preferably 
O(CH), CO-oligonucleotide where n is 1-7 and preferably 
1-3. In other presently preferred embodiments, R-Ro are 
as in Table 1 for texaphyrins A1-A38. 
Texaphyrins of structure B having a substituent on a 
pyrrole nitrogen are provided as new compositions of mat 
ter. Table 2 of Example 2 presents a summary of substituents 
contemplated for this derivatized texaphyrin. The pyrrole 
nitrogen substituent (R) may be alkyl, alkenyl, 









atoms; with the provision that the substituent has rotational 
flexibility after the first-bound carbon to allow the rest of the 
group to be positioned outside the plane of the texaphyrin. 
Thus, a preferred alkenyl is CH-CH=CH2. The pyrrole 
nitrogen substituent is most preferably a methyl group. 
A further embodiment of the present invention is a 
method for synthesizing a texaphyrin having a substituent 
(R) on a pyrrole nitrogen. The method comprises the steps 
of i) mixing, in an organic solvent, a nonaromatic texaphyrin 
having a substituent on a pyrrole nitrogen, a Bronsted base 
and an oxidant; and ii) stirring at ambient temperature or 
heating the mixture at reflux for at least two hours. The 
nonaromatic texaphyrin is produced by condensation of a 
tripyrrane aldehyde or ketone having structure I; and a 
substituted ortho-phenylenediamine having structure II: 
R R R3 R. R. R 
Rs / V / V / W Rio 
N N N 





R-R and R-R are independently hydrogen, halide 
other than iodide, hydroxyl, alkyl, aryl, haloalkyl other than 
iodoalkyl. nitro. formyl, acyl, hydroxyalkyl, oxyalkyl, 
oxyhydroxyalkyl, saccharide, aminoalkyl, oxyaminoalkyl, 
carboxy, carboxyalkyl, carboxyamidealkyl, a site-directing 
molecule or a couple to a site-directing molecule. Rs and Rio 
are independently hydrogen, alkyl, aryl, hydroxyalkyl. 
oxyalkyl, oxyhydroxyalkyl, aminoalkyl, oxyaminoalkyl. 
carboxyalkyl, carboxyamidealkyl or a couple to a site 
directing molecule; and R is alkyl, alkenyl, oxyalkyl or 
hydroxyalkyl having up to about 3 carbon atoms and having 
rotational flexibility around a first-bound carbon atom. 
In a preferred method of synthesis, R is methyl, the 
Bronsted base is triethylamine or N.N.N.N-tetramethyl-1, 
8-diaminonaphthalene ("proton sponge”), the oxidant is air 
and the air is saturating the organic solvent, or the oxidant 
may be oxygen, platinum oxide, o-chloronyl or 2,3- 
dichloro-5,6-dicyano-1,4-benzoquinone. The stirring or 
heating at reflux step may comprise stirring or heating at 
reflux the mixture for at least 2 hours and up to about 24 
hours, and the organic solvent may comprise methanol, 
methanol and chloroform, or methanol and benzene, or 
methanol and dimethylformamide. 
The pharmaceutical preparations of the present invention 
may be administered alone or in combination with pharma 
ceutically acceptable carriers, in either single or multiple 
doses. Suitable pharmaceutical carriers include inert solid 
diluents or fillers, sterile aqueous solution and various 
organic solvents. The pharmaceutical compositions formed 
by combining a texaphyrin of the present invention and the 
pharmaceutically acceptable carriers are then easily admin 
istered in a variety of dosage forms such as injectable 
solutions. 
For parenteral administration, solutions of the texaphyrin 
in sesame or peanut oil, aqueous propylene glycol. or in 
sterile aqueous solution may be employed. Such aqueous 
solutions should be suitably buffered if necessary and the 
liquid diluent first rendered isotonic with sufficient saline or 
glucose. These particular aqueous solutions are especially 
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suitable for intravenous, intramuscular, subcutaneous and 
intraperitoneal administration. In this connection, sterile 
aqueous media which can be employed will be known to 
those of skill in the art in light of the present disclosure. 
The pharmaceutical forms suitable for injectable use 
include sterile aqueous solutions or dispersions and sterile 
powders for the extemporaneous preparation of sterile 
injectable solutions or dispersions. In all cases the form must 
be sterile and must be fluid to the extent that easy use with 
a syringe exists. It must be stable under the conditions of 
manufacture and storage and must be preserved against the 
contaminating action of microorganisms, such as bacteria 
and fungi. The carrier can be a solvent or dispersion medium 
containing, for example, water, ethanol, polyol (for example, 
glycerol, propylene glycol, and liquid polyethylene glycol, 
and the like), suitable mixtures thereof, and vegetable oils. 
The proper fluidity can be maintained, for example, by the 
use of a coating, such as lecithin, by the maintenance of the 
required particle size in the case of dispersion and by the use 
of surfactants. The prevention of the action of microorgan 
isms can be brought about by various antibacterial and 
antifungal agents, for example, parabens, chlorobutanol, 
phenol, sorbic acid, thimerosal, and the like. In many cases, 
it will be preferable to include isotonic agents, for example, 
Sugars such as mannitol or dextrose or sodium chloride. A 
more preferable isotonic agent is a mannitol solution of 
about 2-8% concentration, and, most preferably, of about 
5% concentration. Prolonged absorption of the injectable 
compositions can be brought about by the use in the com 
positions of agents delaying absorption, for example. alu 
minum monostearate and gelatin. 
Sterile injectable solutions are prepared by incorporating 
the active compounds in the required amount in the appro 
priate solvent with various of the other ingredients enumer 
ated above, as required, followed by filtered sterilization. 
Generally, dispersions are prepared by incorporating the 
various sterilized active ingredients into a sterile vehicle 
which contains the basic dispersion medium and the 
required other ingredients from those enumerated above. In 
the case of sterile powders for the preparation of sterile 
injectable solutions, the preferred methods of preparation 
are vacuum-drying and freeze-drying techniques which 
yield a powder of the active ingredient plus any additional 
desired ingredient from a previously sterile-filtered solution 
thereof. 
As used herein, "pharmaceutically acceptable carrier" 
includes any and all solvents, dispersion media, coatings. 
antibacterial and antifungal agents, isotonic and absorption 
delaying agents and the like. The use of such media and 
agents for pharmaceutically active substances is well known 
in the art. Except insofar as any conventional media or agent 
is incompatible with the active ingredient, its use in the 
therapeutic compositions is contemplated. Supplementary 
active ingredients can also be incorporated into the compo 
sitions. 
Following long-standing patent law convention, the terms 
'a' and "an" mean "one or more" when used in this 
application, including the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of specific 
embodiments presented herein. 
FIG. 1A, FIG. 1B and FIG. 1C show the synthesis of a 












12-bis(2-[2-(2-methoxyethoxyethylethyl-320,2526, 27-pentaazapentacyclo[20.2.1.1.1",0' heptacosa-1. 
3,5,7,9,11(27), 12.14(19), 15, 17.20,22(25), 23-tridecaene. 
FIG. 2 shows the synthesis of a derivatized texaphyrin 
having an substituent on a pyrrole nitrogen, 2. 
FIG. 3A. FIG. 3B. and FIG. 3C show stepwise synthesis 
schemes for preparing texaphyrin metal complex 
oligonucleotide conjugates. FIG. 3A shows the synthesis of 
a texaphyrin metal complex 3'-linked-oligonucleotide con 
jugate. FIG. 3B and FIG. 3C show an approach that results 
in a 5' linked oligonucleotide conjugate. The circle with a 
squiggle represents controlled pore silica with a linker 
group. 
FIG. 4 shows pulse radiolysis in aqueous isopropyl alco 
hol. The optical density is plotted versus time in useconds 
for the formation of the gadolinium texaphyrin at-radical 
cation, GdT2B2". 
FIG. 5A and FIG. 5B show the decay of the C-radical 
cation formed in FIG. 4 versus time in mseconds. The plot 
in 5A demonstrates that the cation has a long half life 
k=(1.7+.5)x10M's 'I that is not affected by the presence 
of oxygen as shown in 5B (k=(19.7)x10 Ms). These 
data indicate that the GdT2B2" t-radical cation has a 
lower reduction potential than oxygen and therefore does not 
pass its electrons to oxygen. 
FIG. 6 shows the rate constant for the covalent modifi 
cation of cytosine by the texaphyrin radical, GdT2B2(H) 
cks 10 M's '). These data indicate that the texaphyrin 
radical, while relatively stable, is nevertheless reactive and 
will cause damage to neighboring molecules. 
FIG.7 shows the killing of mouse L1210 cells versus dose 
of radiation (in Grays) in the presence and absence of 20 M 
GdB2T2. The sensitizer enhancement ratio is 1.62. 
FIG. 8 shows the effect: of GdB2T2 on L1210 cell kill. 
Sensitizer enhancement ratios are plotted versus concentra 
tion of GdB2T2. An SER greater than 1.5 is clinically 
significant. These data indicate that the effectiveness of 
GdB2T2 as a sensitizer increases with the concentration 
achieved. 
FIG. 9 shows the effect of GdB2T2 on nucleic acid 
strand scission under radiolysis at 25 grays. L1210 cells 
were exposed to GdB2T2' at the indicated concentrations. 
lysed and the nucleic acid material passed through a size 
selection filter. 
F.G. 10A and F.G. 10B show radiation sensitization of 
human HT-29 tumor cells using texaphyrins. FIG. 10A 
shows cell kill without texaphyrin (O) and in the presence 
of GdT2B2" (A), GdT2BET* (0), and LuT2BET''' (). 
FIG. 10B shows cell kill in the absence () and presence of 
GdT2BET''' at 10 uM (), 20 M (4) and 40 uM (A) 
concentrations. 
FIG. 11A, FIG. 11B, FIG. 11C and FIG. 11D show overall 
survival and primary cancer-free survival (complete 
responders) for animals administered radiation and T2BET 
(40 mol/kg injection) and those given radiation alone 
(control) for all animals dosed at 20 Gray (FIG. 11A and 
FIG. 11B) and 30 Gray (FIG. 11C and FIG. 11D). Four 
animals were in each group and radiation occurred 2 hours 
after the texaphyrin injection. Symbols are: c. radiation only, 
overall survival: , radiation only, cancer-free survival; A. 
T2BET and radiation, overall survival; A T2BET and 
radiation, cancer-free survival. 
DETALED DESCRIPTION OF THE 
PREFERRED EMBODMENTS 
The present invention involves the use of texaphyrins for 
radiosensitization in radiation therapy, and for a two 
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pronged treatment protocol involving radiation therapy and 
photodynamic tumor therapy. More particularly, the inven 
tion demonstrates enhanced cytotoxicity from radiation and 
enhanced nucleic acid strand scission in the presence of a 
texaphyrin. Examples 1-4 describe the synthesis of pre 
ferred texaphyrins and texaphyrins conjugated to site 
directing molecules. Examples 5-8 describe the use of 
texaphyrins for radiosensitization, radiation therapy and 
radiation therapy with photodynamic tumor therapy. 
The synthesis of texaphyrins is described in U.S. Pat. Nos. 
4.935.498, 5,162,509, 5.252.720 and 5.457.183 U.S. appli 
cations Ser. Nos. 08/098.514 08/196,964 08/227,370 and 
08/294344; all of which are incorporated by reference 
herein. Substituents at the R-R positions on the B 
(benzene ring) portion of the macrocycle are incorporated 
into the macrocycle by their attachment to the precursor, 
ortho-phenylenediamine in the 3, 4, 5, and 6 positions of the 
15 
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molecule. The introduction of substituents on the T 
(tripyrrane) portion of the molecule is accomplished by 
appropriate functionalization of the pyrrole rings, and sub 
stituents at the Rs and Ro positions are incorporated by 
appropriate functionalization of the tripyrrane in the 5 
positions at a synthetic step prior to condensation with a 
substituted ortho-phenylenediamine. More preferred func 
tionalizations are: when R and R are other than hydrogen. 
then Rs and Ro are hydrogen or methyl; and when Rs and 
Ro are other than hydrogen, then R6 and R are hydrogen, 
hydroxyl, or halide other than iodide. 
Any texaphyrin or texaphyrin metal complex may be used 
as a radiation sensitizer. Representative substituents of pre 
ferred texaphyrins of structure A for radiation sensitization 





A substituent on the Rs or Ro position of the macrocycle 
may be derivatized either before or after condensation of the 
macrocycle. Substituents may include an alkyl group having 
up to 5 carbon atoms or a phenyl group that may be further 
derivatized with a nitro, carboxyl, sulfonic acid, hydroxyl, 
halide or alkoxy where the alkyl of the alkoxy may be 
hydroxyalkyl and the like. 
Divalent and trivalent metal complexes of texaphyrins are 
by convention shown with a formal charge of N. where N 
is 1 or 2. respectively. It is understood by those skilled in the 
art that the complexes described in the present invention 
may have one or more additional ligands providing charge 
neutralization and/or coordinative saturation to the metal 
ion. Such ligands include chloride, nitrate, acetate, and 
hydroxide, among others. 
The metal complexes may be associated with, depending 
on the metal, anywhere from 0-6 apical ligands about the 
encapsulated metal center. The ligands are typically some 
combination of acetate, chloride, nitrate, hydroxide, water. 
or methanol and when bound, are not readily dissociable. 
The presence of the metal is not important for the radi 
osensitization properties of texaphyrins; however, the metal 
contributes stability to the texaphyrin complex. A metal 
texaphyrin complex with its counterions is considered a 
neutral complex for purposes of this application; for 
example, GdT2B2(OAc) is a neutral complex. A metal 
complex of texaphyrin, such as GdT2B2" has two positive 
charges. When GdT2B2" picks up an electron, it becomes 
a short-lived ?t-radical cation, GdT2B2". The cation picks 
up a proton or rearranges to the texaphyrin radical, 
GdT2B2(H), which has significant stability as described in 
Example 5. 
Oxygen is the ultimate electron acceptor in physiological 
systems. However, texaphyrins have aredox potential below 
that of oxygen. All reductants will reduce texaphyrin, even 
superoxide, as can be seen from the following listing of 
redox potentials: 
eaq=-2.80 V. 
Porphyrin=-0.6 to -1.8 V. 
Quinone=-0.2 to -1.0 V. 
O=-0.18 V. 
GdT2B2-+0.08 V. 
Therefore, gadolinium texaphyrin “soaks up" electrons 
readily, and prevents their reaction with hydroxyl radicals or 
other oxidized species. This low redox potential of gado 
linium texaphyrin is a property of texaphyrin that enhances 
the amount of radiation damage incurred at the site of the 
texaphyrin; in the absence of texaphyrin, hydroxyl radicals 
and hydrated electrons recombine and little radiation dam 
age occurs, whereas in the presence of texaphyrin, hydroxyl 
radicals are free to cause damage. Furthermore, the trapping 
of electrons by texaphyrin prevents the hydrated electrons 
from interacting with the hydroxyl radical-induced damage 
site to repair the damage. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. Although any methods and materials 
similar or equivalent to those described herein can be used 
in the practice or testing of the present invention, the 
preferred methods and materials are now described. Unless 
mentioned otherwise, the techniques employed herein are 
standard methodologies well known to one of ordinary skill 
in the art. 
EXAMPLE 1. 
Synthesis of Texaphyrin T2BET 
The present example provides the synthesis of a preferred 












Lutetium(III) acetate hydrate was purchased from Stren 
Chemicals, Inc. (Newburyport, Mass.) and gadolinium(III) 
acetate tetrahydrate was from Aesar/Johnson Matthey (Ward 
Hill, Mass.). The LZY-54 zeolite was purchased from UOP 
(Des Plaines. Ill.). Acetone, glacial acetic acid, methanol. 
ethanol, isopropyl alcohol, and n-heptanes were purchased 
from J. T. Baker (Phillipsburg, N.J.), Triethylamine and 
Amberlite 904 anion exchange resin were purchased from 
Aldrich (Milwaukee, Wis.). All chemicals were ACS grade 
and used without further purification. 
Synthesis of the gadolinium (III) complex of 4,5-diethyl 
10,23-dimethyl-9.24-bis(3-hydroxypropyl)-16,17-bis(2-2- 
(2-methoxyethoxy)ethoxyethoxy)-pentaazapentacyclo 
20.2.1.1. 1.0-heptacosa-1,3,5,79.11(27), 12.14, 
16.13.20.22(25).23-tridecaene (1 FIG. 1A, FIG. 1B AND 
FIG. 1C). The critical intermediate 1.2-bis(2-2-(2- 
methoxyethoxy)ethoxyethoxy-4,5-dinitrobenzene, 1 was 
prepared according to the three-step synthetic process out 
lined in FIG. A. 
Synthesis of triethylene glycol monomethyl ether 
monotosylate. 1: In an oven dried 12 L three-necked 
round-bottom flask, equipped with a magnetic stir bar and a 
1000 mL pressure-equalizing dropping funnel, a solution of 
NaOH (440.0 g, 11.0 mol) in water (1800 mL) was added, 
and the mixture was cooled to 0°C. A solution of triethylene 
glycol monomethyl ether 1 (656.84 g. 4.0 mol) in THF 
(1000 mL) was added. The clear solution was stirred wig 
orously at 0°C. for 15 min and a solution of tosyl chloride 
(915.12, 4.8 mol) in THF (2.0 L) was added dropwise over 
a 1 h period. The reaction mixture was stirred for an 
additional 1 h at 0°C., and 10% HCl (5.0 L) was added to 
quench the reaction (to pH 5-7). The two-phase mixture was 
transferred in portions to a 4 L separatory funnel, the organic 
layer removed, and the aqueous layer extracted with 
t-butylmethyl ether (3x250 mL). The combined organic 
extracts were washed with brine (2x350 mL), dried 
(MgSo), and evaporated under reduced pressure to afford 
1, 1217.6 g (95%) as a light colored oil. This material was 
taken to the next step without further purification. 
Synthesis of 1.2-bis(2-2-(2-methoxyethoxy)ethoxyl 
ethoxy-benzene 1. In a dry 5 L round-bottom flask 
equipped with an overhead stirrer, reflux condenser, and a 
gas line, KCO (439.47 g. 3.18 mol) and MeOH (1800 mL) 
were combined under an argon atmosphere. To this well 
stirred suspension, catechol 1 (140.24 g, 1.27 mol) was 
added, and the mixture was heated to reflux. 1 (1012.68 g. 
3.18 mol) was then added in one portion. The suspension 
was stirred at reflux for 24 h., cooled to room temperature, 
and filtered through Celite. The pad was rinsed with 500 mL 
of methanol and the combined filtrates were evaporated 
under reduced pressure. The resulting brown residue was 
taken up in 10% NaOH (800 mL), and methylene chloride 
(800 mL) was added with stirring. The mixture was trans 
ferred to a 2 L separatory funnel, the organic layer removed 
and the aqueous layer extracted with methylene chloride 
(3x350 mL). The organic extracts were combined, washed 
with brine (350 mL), dried (MgSO), evaporated under 
reduced pressure, and the residue dried in vacuo for several 
hours to yield 485.6 g (95%) of 1.2-bis(2-2-(2- 
methoxyethoxy)ethoxyethoxybenzene 1. For 1: bp. 
165°-220° C., (0.2-0.5 mm Hg); FAB MS. M': mile 402; 
HRMS. M.: 402.2258 (calcd. for CHOs, 402.2253). 
Synthesis of 1.2-bis(2-[2-(2-methoxyethoxy)ethoxy 
ethoxy-4,5-dinitrobenzene 1. In an oven dried 1 L round 
bottom flask, 1 (104 g. 0.26 mol) and glacial acetic acid 
(120 mL) were combined and cooled to 5° C. To this well 
stirred solution, concentrated nitric acid (80 mL) was added 
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dropwise over 15-20 min. The temperature of the mixture 
was held below 40° C. by cooling and proper regulation of 
the rate of addition of the acid. After addition the reaction 
was allowed to stir for an additional 10-15 min and was then 
cooled to 0° C. Fuming nitric acid (260 mL) was added 
dropwise over 30 min while the temperature of the solution 
was held below 30° C. After the addition was complete. the 
red colored solution was allowed to stir at room temperature 
until the reaction was complete (ca. 5h, TLC: 95/5; CHCly 
MeOH) and then poured into well stirred ice water (1500 
mL). Methylene chloride (400 mL) was added, the two 
phase mixture was transferred to a 2 L separatory funnel and 
the organic layer was removed. The aqueous layer was 
extracted with CHCl2(2x150 mL) and the combined 
organic extracts were washed with 10% NaOH (2x250 mL) 
and brine (250 mL), dried (MgSO), and concentrated under 
reduced pressure. The resulting orange oil was dissolved in 
acetone (100 mL), and the solution layered with n-hexanes 
(500 mL), and stored in the freezer. The resulting precipitate 
was collected by filtration to yield 101.69 g (80%) of 1, as 
a yellow solid. For 1: mp 43°45° C.; FAB MS, (M+H)": 
m/e 493; HRMS. (M+H): 493.2030 (calcd. for 
CoH3NO2. 493.2033). 
Synthesis of 1,2-diamino-4,5-bis 2-[2-(2- 
methoxyethoxy)ethoxyethoxybenzene. 1, FIG. 1B. In an 
oven dried 500 mL round bottom flask, equipped with a 
Claisen adapter, pressure equalizing dropping funnel, and 
reflux condenser, 1.2-bis(2-2-(2-methoxyethoxy)ethoxy 
ethoxy-4,5-dinitrobenzene 1 (20 g, 0.04 mol) was dis 
solved in absolute ethanol (200 mL). To this clear solution, 
10% palladium on carbon (4 g) was added and the dark black 
suspension was heated to reflux under an argon atmosphere. 
Hydrazine hydrate (20 mL) in EtOH (20 mL) was added 
dropwise over 10 min to avoid bumping. The resulting 
brown suspension was heated at reflux for 1.5 h at which 
time the reaction mixture was colorless and TLC analysis 
(95/5; CH,Cl/MeOH) displayed a low R UV active spot 
corresponding to the diamine. Therefore, the mixture was 
hot filtered through Celite and the pad rinsed with absolute 
ethanol (50 mL). The solvent was removed under reduced 
pressure and the resulting light brown oil was dried in vacuo 
(in the dark) for 24 h to yield 15.55g (89%) of 1,2-diamino 
bis(2-[2-(2-methoxyethoxy)ethoxyethoxybenzene 1. For 
1: FAB MS.M: m/e 432; HRMS.M":432.2471 (calcd. for 
CoHNOs, 432.2482). This material was taken to the next 
step without further purification. 
Synthesis of 4,5-diethyl-10.23-dimethyl-9.24-bis(3- 
hydroxypropyl)-16,17-bis(2-2-(2-methoxyethoxy)ethoxy 
ethoxy)-13.20.25,26.27-pentaazapentacyclo[20.2.1.1.18, 
11.0''']heptacosa-3.5.8.10, 12.14.16, 18.20.22.24 
undecaene (1). In an oven dried 1 L round-bottom flask, 
2.5-bis(5-formyl-3-(3-hydroxypropyl)-4-methyl-pyrrol-2- 
yl)methyl)-3,4-diethylpyrrole 1 (The synthesis of 1 is 
provided in U.S. Pat. No. 5.252.720, incorporated by refer 
ence herein.) (30.94) g. 0.0644 mol) and 4.5-diamino-bis(2- 
(2-(2-methoxyethoxy)ethoxyethoxybenzene 1 (28.79 g, 
0.0644 mol) were combined in absolute methanol (600 mL) 
under an argon atmosphere. To this well stirred suspension, 
a mixture of concentrated hydrochloric acid (6.7 mL) in 
absolute methanol (200 mL) was added in one portion. The 
mixture was gradually heated to 50° C. at which time the 
reaction went from a cloudy suspension of starting materials 
to a dark red homogeneous solution as the reaction pro 
ceeded. After 3h the reaction was judged complete by TLC 
analysis and UV/visible spectroscopy (A 369 mm). The 
reaction mixture was cooled to room temperature, 60 g of 












suspension was stirred for 20 min. The dark suspension was 
filtered through Celite to remove the carbon, the solvent 
evaporated to dryness, and the crude 1 dried in vacuo 
overnight. 1 was recrystallized from isopropyl alcohol/n- 
heptane to afford 50 g (85%) of a scarlet red solid. For 1: 
"H NMR (CDOD): 81.11 (t. 6H, CHCH), 1.76 (p. 4H. 
pyrr-CH2CH2CH2OH), 2.36 (s, 6H. pyrr-CH), 2.46 (q. 4H. 
CHCH), 2.64 (t, 4H. pyrr-CHCHCH-OH), 3.29 s. 6H, 
(CHCHO)CH), 3.31 (t, 4H. pyrr-CHCHCHOH). 
3.43-3.85 (m. 20HCHCHOCH, CHOCHCHO). 4.10 
(s, 4H. (pyrr)-CH), 4.22 (t, 4H. PhOCHCHO), 7.45 (s. 
2H, Ph.H), 8.36 (s. 2H, HC-N); UV/vis: (MeOH) 
nm.): 369; FAB MS, M+H": me 878.5; HRMS, M+H: 
mile 878.5274 (calcd. for CHNO+, 878.5279). 




16, 1820.22(25).23-tridecaene 1. 1 was prepared according 
to the process outlined in FIG. 1C. In a dry 2 L three-necked 
round-bottom flask, 1 (33.0 g. 0.036 mol) and gadolinium 
(III) acetate tetrahydrate (15.4g. 0.038 mol) were combined 
in methanol (825 mL). To this well stirred red solution. 
gadolinium(III) acetate tetrahydrate (15.4 g 0.038 mol) and 
triethylamine (50 mL) were added and the reaction was 
heated to reflux. After 1.5 h, air was bubbled (i.e. at reflux) 
for 4h into the dark green reaction solution with aid of a gas 
dispersion tube (flow rate=20 cm/min). At this point, the 
reaction mixture was carefully monitored by UV/Visible 
spectroscopy (i.e. a spectrum is taken every 0.5-1 h,-1 drop 
diluted in 4-5 mL MeOH). The reaction was deemed com 
plete by UV/Vis (In MeoH ratio: 342 nm/472 
nm=0.22-0.24) after 4 h. The dark green reaction was 
cooled to room temperature, filtered through Celite into a 2 
L round-bottom flask, and the solvent removed under 
reduced pressure. The dark green solid was suspended in 
acetone (1 L) and the resulting slurry was stirred for 1 h at 
room temperature. The suspension was filtered to remove 
the red/brown impurities (incomplete oxidation products). 
the solids rinsed with acetone (200 mL), and air dried. The 
crude complex (35 g) was dissolved in MeoH (600 mL). 
stirred vigorously for 15 min, filtered through Celite, and 
transferred to a 2 L Erlenmeyer flask. An additional 300 mL 
of MeCH and 90 mL water were added to the flask, along 
with acetic acid washed LZY-54 zeolite (150 g). The sus 
pension was agitated with an overhead mechanical stirrer for 
approximately 3–4 h. The Zeolite extraction is deemed 
complete with the absence of free Gd(III). To test for free 
gadolinium, the crude 1 was spotted heavily onto a reverse 
phase TLC plate (Whatman KC8F, 1.5x10 cm) and the 
chromatogram developed using 10% acetic acid in metha 
nol. The green complex moved up the TLC plate close to the 
solvent front. Any free gadolinium metal will remain at the 
origin under these conditions. After developing the 
chromatogram, the plate was dried and the lower % of the 
plate stained with an Arsenazo III solution in methanol (4 
mg Arsenazo III in 10 mL methanol). A very faint blue spot 
(indicative of free metal) was observed at the origin against 
a pink background indicating very little free gadolinium 
metal. The zeolite was removed through a Whatman #3 
filter paper and the collected solids rinsed with MeOH (200 
mL). The dark green filtrate was loaded onto a column of 
Amberlite IRA-904 anion exchange resin (30 cm length}x2.5 
cm diameter) and eluted through the resin (ca. 10 mL/min 
flow rate) into a 2 L round bottom flask with 300 mL 
1-butanol. The resin was rinsed with an additional 100 mL 
of MeOH and the combined eluent evaporated to dryness 
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under reduced pressure. The green shiny solid 1 was dried 
in vacuo for several hours at 40°C. To a well stirred ethanoic 
solution (260 mL) of 1 at 55°-60° C. n-heptanes (ca. 600 
mL) was added dropwise (flow-4 mL/min) from a 1 L 
pressure-equalizing dropping funnel. During the course of 
1.5 h (300 mL addition) the green complex. 1 began to 
crystallize out of the dark mixture. After complete addition, 
the green suspension was cooled and stirred for 1 h at room 
temperature. The suspension was filtered, the solids rinsed 
with acetone (250 mL), and dried in vacuo for 24 h to afford 
26 g (63%). UV/vis: (MeOH) A nm): 316, 350, 415. 
473, 739; FAB MS. (M-20Ac); m/e 1030; HRMS. 
(M-20Ac)": me 1027.4036 (calcd, for CH'GdNOo. 
1027.4016). Anal. calcd. for (C.H.GdN,0-0.5H2O: C. 
53.96; H, 6.36: N, 6.05, Gd, 13.59. Found: C, 53.73; H, 6.26; 
N, 5.82; Gd, 13.92. 
Synthesis of the Lutetium(III) Complex of 1. The mac 
rocyclic ligand 1 (14 g, 0.0153 mol) was oxidatively 
metallated using lutetium(III) acetate hydrate (9.75 g, 
0.0230 mol) and triethylamine (22 mL) in air-saturated 
methanol (1500 mL) at reflux. After 3-4 hat reflux. air was 
bubbled for 40 min into the dark brown/green reaction 
solution with aid of a gas dispersion tube (flow rate=20 
cm/ml). At this point, reflux continued overnight. After 23 
h, air was re-bubbled an additional 40 minto complete the 
oxidation/metallation. The reaction continued at reflux for 5 
h and then it was judged complete by the characteristic 
UV-visible spectrum. The deep green solution was cooled to 
room temperature, filtered through a pad of celite, and the 
solvent removed under reduced pressure. The dark green 
solid was suspended in acetone (600 mL), stirred for 30 min 
at room temperature, and then filtered to wash away the 
red/brown impurities (incomplete oxidation products and 
excess triethylamine). The crude complex was dissolved 
into MeOH (300 mL), stirred for -30 min, and then filtered 
through celite into a 1 LErlenmeyer flask. An additional 50 
mL of MeOH and 50 mL of water were added to the flask 
along with acetic acid washed LZY-54 zeolite (40 g). The 
resulting mixture was agitated or shaken for 3 h. then filtered 
to remove the Zeolite. The zeolite cake was rinsed with 









The filtrate was first concentrated to 150 mL and then loaded 
onto a column (30 cm lengthX2.5 cm diameter) of pretreated 
Amberlite IRA-904 anion exchange resin (resin in the 
acetate form). The eluent containing the bis-acetate lutetium 
(III) texaphyrin complex was collected, concentrated to 
dryness under reduced pressure, and recrystallized from 
anhydrous methanol/t-butylmethyl ether to afford 11.7 g 
(63%) of a shiny green solid. For the complex: UV/vis: 
(MeOH) nm (log e)): 354.414474 (5.10), 672. 732; 
FAB MS. M-OAct: me 1106.4; HRMS. M-OAc): 
mfe 1106.4330 (calcd. for CHLuNOo(OAc), 
1106.4351). Anal. calcd. for CHLuNOHO: C, 
52.74; H, 6.30; N, 5.91. Found: C, 52.74; H, 6.18: N, 5.84. 
EXAMPLE 2 
Texaphyrin Derivatized at a Pyrrole Nitrogen 
A further texaphyrin macrocycle is one where a pyrrole 
nitrogen is derivatized. FIG. 2 shows the synthesis of such 
an N-substituted texaphyrin where an R group is attached 
to the nitrogen of the central pyrrole of the precursor 
tripyrrole 2. Wang et al., (1977) provides one method for 
N-alkylation of pyrrole. The synthesis of texaphyrin com 
pounds having substituents R. R. R. and Rio as shown in 
FIG. 2 is described in USSN 08/196,964, incorporated by 
reference herein. The free base macrocycle is particularly 
useful when fluorescence detection is used as the localiza 
tion means for radiation sensitization. Optical characteristics 
of various texaphyrin complexes are described in Sessler et 
al. (1991), incorporated by reference herein. 
Table 2 presents a summary of substituents contemplated 
for the pyrrole-nitrogen derivatized texaphyrin 2. For this 
texaphyrin, R2 and R are preferably ethyl and R is pref 
erably methyl. R may be a lower alkyl. alkenyl, 
hydroxyalkyl, or alkoxy group having up to about 3 carbon 
atoms; with the provision that the group has rotational 
flexibility around the first-bound carbon to allow the rest of 
the group to be positioned outside the plane of the texaphy 
rin. Thus, a preferred alkenyl is CH-CH=CH2. R is most 
preferably a methyl group. 
TABLE 2 
REPRESENTATIVE SUBSTITUENTS FOR TEXAPHYRIN 2 OF FIG, 2 
Cpd. R. Rs R R 
B1 OCHCH-OH OCHCHCHOH OCHCHCH-OH CH, 
B2 CHCH OCHCHCH-OH OCHCHCH-OH CH 
B3 CHCHCH-OH OCHCHCH-OH OCHCHCH-OH CH 
B4 CHCHCH-OH O(CHCHO).H O(CHCHO).H CH, 
B5 CHCHCHOH O(CHCHO)CH O(CHCHO)CH, CH, 
B6 CHCHCH-OH OCH OCHCOOH CH 
B7 CHCHCH-OH OCHCOOH OCHCOOH CH 
B8 CHCHCH-OH O(CHCHO)CH OCHCOOH CH, 
B9 CHCHCONHCH(CHOH), OCHCH-OH OCHCH-OH CH, 
B10 CHCHCON(CHCH-OH), OCHCHOH OCHCH,OH CH 
B11 CHCHCHOH O(CHCHO)CH, OCH, CH, 
B12 CHCHCH-OH OCHCHCHCOOH H CHCH 
B13 CHCHCH-OH OCHCHCH-OH OCHCHCH-OH CHCH, 
B14 CHCHCH-OH O(CHCHO)CH, O(CHCHO)CH, CHCH, 
B15 CHCHCH-OH OCHCHO)CH O(CHCHO)CH, CHCH=CH 
B 16 CHCHCH-OH O(CHCHO)CH O(CHCHO)CH, CHCH-OH 
B17 CHCHCH-OH O(CHCHO)CH, O(CHCHO),CH, CH,CHOCH, 
B18 CHCHCH-OH O(CHCOOH H CH 
where n = 1-7 
B19 CHCHCH-OH O(CHCHO)CH, O(CHCHO)CH, CH, 
where n = 1-200 where n = 1-200 




REPRESENTATIVE SUBSTITUENTS FORTEXAPHYRIN 2 OF FIG. 2 



















where n = 1-7 
O(CHCON-linker 
oligonucleotide 
where n is - 
B21 CHCHCH-OH 
B22 CHCHCH-OH H 
B23 H CHCHCHOH 
B24 CHCHCH-OH H 
B25 CHCHCH-OH 
B26 CHCHCH-OH H 
B27 CHCHCH-OH 
B28 H CHCHCHOH 
EXAMPLE 3 
Texaphyrin Site-Directing Conjugates 
The use of texaphyrins as radiation sensitizers in vivo as 
part of a treatment procedure relies on the effective local 
ization of the texaphyrin to the treatment site. Texaphyrins 
have intrinsic biolocalization properties, localizing in lipo 
philic tissue such a liver, tumor and atheroma, for example, 
as described in U.S. Pat. No. 5.252.720, incorporated by 
reference herein. Further localization specificity may be 
achieved by conjugating the texaphyrin or texaphyrin-metal 
complex to a site-directing molecule such as a polynucle 
otide or oligonucleotide, for example, an antisense 
oligonucleotide, as described in Example 4; a polyamide 
including a peptide having affinity for a biological receptor 
or a protein such as an antibody, low density lipoprotein 
(LDL) or the APO-protein of LDL; a steroid or steroid 
derivative; a hormone such as estradiol or histamine; a 
hormone-mimic such as morphine; a dye or other compound 
having binding specificity for a target; or a further macro 
cycle such as a sapphyrin or rubyrin. 
Texaphyrins are especially suited for acting as bifunc 
tional chelating agents in antibody conjugate-based treat 
ment since they have functional groups suitable for conju 
gation to the antibody. They form covalent linkages that are 
stable in vivo and do not destroy the immunological com 
petence of the antibody, they are relatively nontoxic... they 
bind metals and retain the metal of interest under physi 
ological conditions, and they are readily soluble in a physi 
ological environment. A further advantage of these texaphy 
rins is that many would be suitable for further 
functionalization. Treatment of carboxylated texaphyrins 
with thionyl chloride or p-nitrophenol acetate would gener 
ate activated acyl species suitable for attachment to mono 
clonal antibodies or other site-directing molecules of inter 
est. Standard in situ coupling methods (e.g. 1.1'- 
carbonyldiimidazole (CDI)) could be used to effect the 
conjugation. 
Another means of gaining selectivity may be to link 
covalently the texaphyrin complex to a sapphyrin molecule, 


















U.S. Pat. No. 5,159,065; U.S. Pat. No. 5,120,411; U.S. Pat. 
No. 5,041.078). Since sapphyrins bind DNA, K-10 M", 
(U.S. Pat. No. 5.457.195, incorporated by reference herein) 
the linked texaphyrin-sapphyrin complex could effectively 
increase the texaphyrin concentration at locations adjacent 
to the sapphyrin binding sites. Sapphyrins have a higher 
fluorescent quantum yield than texaphyrins, allowing greater 
fluorescence detection. A laser system may be employed 
where the molecules are optimized to the laser wavelength; 
an excited sapphyrin may transfer its energy to the conju 
gated texaphyrin for detection. The texaphyrin molecule 




The present example provides synthetic procedures where 
a texaphyrin is coupled to an oligonucleotide or analog 
thereof, or is incorporated into the synthesis scheme of an 
oligonucleotide or analog thereof, to provide a texaphyrin 
oligonucleotide or texaphyrin-oligonucleotide analog con 
jugate having binding specificity for a complementary oli 
gonucleotide. 
Amides, ethers, and thioethers are representative of link 
ages which may be used for coupling site-directing mol 
ecules such as oligonucleotides to texaphyrins. Oligonucle 
otides or other site-directing molecules functionalized with 
amines at the 5'-end, the 3'-end, or internally at sugar or base 
residues are modified post-synthetically with an activated 
carboxylic ester derivative of the texaphyrin. In the presence 
of a Lewis acid such as FeBr, a bromide derivatized 
texaphyrin will react with an hydroxyl group of an oligo 
nucleotide to form an ether linkage between the texaphyrin 
linker and the oligonucleotide. Alternatively, oligonucle 
otide analogues containing one or more thiophosphate or 
thiol groups are selectively alkylated at the sulfur atom(s) 
with an alkyl halide derivative of the texaphyrin. 
Oligodeoxynucleotide-complex conjugates are designed so 
as to provide optimal catalytic interaction between the 
targeted DNA phosphodiester backbone and the texaphyrin. 
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For general reviews of synthesis of DNA, RNA, and their 
analogues, see Oligonucleotides and Analogues, F. Eckstein, 
Ed., 1991, IRL Press, New York, Oligonucleotide Synthesis, 
M. J. Gait, Ed., 1984, IRL Press Oxford, England; Carac 
ciolo et al. (1989); Bioconjugate Chemistry, Goodchild, J. 
(1990); or for phosphonate synthesis, Matteucci, MD. et al., 
Nucleic Acids Res. 14:5399 (1986) (the references are incor 
porated by reference herein). 
In general, there are three commonly used solid phase 
based approaches to the synthesis of oligonucleotides con 
taining conventional 5'-3' linkages. These are the phos 
phoramidite method, the phosphonate method, and the 
triester method. 
A brief description of a current method used commer 
cially to synthesize oligomeric DNA is as follows: Oligo 
mers up to ca. 100 residues in length are prepared on a 
commercial synthesizer, eg. Applied Biosystems Inc. (ABI) 
model 392, that uses phosphoramidite chemistry. DNA is 
synthesized from the 3' to the 5' direction through the 
sequential addition of highly reactive phosphorous(III) 
reagents called phosphoramidites. The initial 3' residue is 
covalently attached to a controlled porosity silica solid 
support, which greatly facilitates manipulation of the poly 
mer. After each residue is coupled to the growing polymer 
chain, the phosphorus(III) is oxidized to the more stable 
phosphorus(V) state by a short treatment with iodine solu 
tion. Unreacted residues are capped with acetic anhydride, 
the 5'-protective group is removed with weak acid, and the 
cycle may be repeated to add a further residue until the 
desired DNA polymer is synthesized. The full length poly 
mer is released from the solid support, with concomitant 
removal of remaining protective groups, by exposure to 
base. A common protocol uses saturated ethanolic ammonia. 
The phosphonate based synthesis is conducted by the 
reaction of a suitably protected nucleotide containing a 
phosphonate moiety at a position to be coupled with a solid 
phase-derivatized nucleotide chain having a free hydroxyl 
group, in the presence of a suitable activator to obtain a 
phosphonate ester linkage, which is stable to acid, Thus, the 
oxidation to the phosphate or thiophosphate can be con 
ducted at any point during synthesis of the oligonucleotide 
or after synthesis of the oligonucleotide is complete. The 
phosphonates can also be converted to phosphoramidate 
derivatives by reaction with a primary or secondary amine in 
the presence of carbon tetrachloride. 
In the triester synthesis, a protected phosphodiester nucle 
otide is condensed with the free hydroxyl of a growing 
nucleotide chain derivatized to a solid support in the pres 
ence of coupling agent. The reaction yields a protected 
phosphate linkage which may be treated with an oximate 
solution to form unprotected oligonucleotide. 
To indicate the three approaches generically, the incoming 
nucleotide is regarded as having an "activated" phosphitef 
phosphate group. In addition to employing commonly used 
solid phase synthesis techniques, oligonucleotides may also 
be synthesized using solution phase methods such as diester 
synthesis. The methods are workable, but in general, less 
efficient for oligonucleotides of any substantial length. 
Preferred oligonucleotides resistant to in vivo hydrolysis 
may contain a phosphorothioate substitution at each base (J. 
Org. Chem., 55:4693-4699, (1990) and Agrawal, (1990)). 
Oligodeoxynucleotides or their phosphorothioate analogues 
may be synthesized using an Applied Biosystem 380B DNA 
synthesizer (Applied Biosystems, Inc., Foster City, Calif.). 
A further synthetic procedure inserts a texaphyrin directly 











support. Texaphyrin macrocycles were not known to be 
stable under the basic conditions employed in the synthesis 
of oligonucleotides. For example, until the results presented 
herein were obtained, it was thought that texaphyrin, being 
a Schiff base, may be unstable to the basic conditions 
employed during oligonucleotide synthesis. specifically dur 
ing the ammonia and ethanol cleavage and deprotection 
steps. 
It is contemplated that the stepwise synthesis provided 
herein may be performed manually or may be automated, 
and may be in a solution-phase or on a solid support. Solid 
support synthesis may be accomplished using an automated 
or a manual nucleic acid synthesizer. Common solid sup 
ports are CPG (control pore glass) and CPS (control pore 
silica). Other possible solid supports include polystyrene, 
polyamide/Kieselguhr, and cellulose paper. A preferred 
embodiment of this method is automated synthesis on a solid 
support. Attachment of a texaphyrin to an oligonucleotide 
during stepwise synthesis obviates the need for a postmodi 
fication protocol and a second purification of the product. 
This results in an improved yield and greatly facilitates 
scale-up. The texaphyrin may be a free base texaphyrin or 
may be a texaphyrin metal complex. 
The finding that Ln(III) texaphyrins, notably DyT2B2* 
and EuT2B1*, are stable to treatment with ethanolic ammo 
nia for 24 h at ambient temperature suggests that it is 
possible to derivatize oligomers with lanthanide(III) texa 
phyrin complexes during stepwise synthesis. 
A texaphyrin or metal complex thereof may be inserted 
into the synthesis scheme of an oligonucleotide in a variety 
of ways. Possible linkages include amide, phosphate, 
thioether, amino, and ether linkages. An amide linkage 
represents the reaction of an activated carboxylic acid 
derivative of a macrocycle and an amino linker attached to 
an oligonucleotide. Activation may be achieved in solution 
phase or on a solid support using DCC and NHS, EDC 
(1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide), or acti 
wated esters of NHS, nitrophenyl, pentachlorophenyl, acid 
anhydride, or sulfonyl chloride. In addition, for the solid 
support reaction, activation may be in the form of an acid 
chloride. A phosphate linkage represents the reaction of an 
activated phosphate derivative of a macrocycle and the 5' 
hydroxyl group on an oligonucleotide. The activated phos 
phate may be a phosphoramidite, an H-phosphonate, a 
triester, or a diester. 
Representative synthetic schemes are discussed here. In 
the approach depicted in FIG. 3A, a metal-texaphyrin com 
plex 3A is attached to a solid support 3A via a six carbon 
amine linker. This amide-forming coupling reaction is cur 
rently employed to attach the complex post-synthetically. It 
is important to note that texaphyrin hydroxyl groups are 
protected as an ester on 3A for stepwise synthesis. These 
protecting groups are labile to the ethanolic ammonia treat 
ment. Such a metal-texaphyrin-derivatized support may be 
used for stepwise synthesis, and upon cleavage and 
deprotection, results in a 3'-linked metal-texaphyrin-DNA 
conjugate 3A. The amide-forming reaction may also occur 
at the conclusion of DNA synthesis before deprotection and 
cleavage from the solid support. 
As depicted in FIG, 3B, a phosphoramidite derivative of 
a metal texaphyrin complex 3B is prepared by reaction of 
the monoalcohol 3B, with phosphitylating agent and diiso 
propylethylamine. The hydroxyl groups are again protected 
as the ester for this synthesis. The resulting phosphoramidite 
is coupled on the synthesizer as the final residue to form3B. 
In this approach. deprotection results in a 5'-linked 
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texaphyrin-metal complex-DNA conjugate 3C. This 
texaphyrin-conjugate has no amide bonds in the linker, 
A texaphyrin-DNA conjugate having the texaphyrin in an 
internal linkage to the oligonucleotide may be synthesized 
using this stepwise approach. A dihydroxytexaphyrin is 
treated with dimethoxytritylchloride in the presence of 
dimethylaminopyridine and pyridine. The resulting mono 
protected texaphyrin is treated with phosphitylating agent 
and diisopropylethylamine to produce a monoprotected 
phosphoramidite. This product is coupled to a growing 
oligonucleotide during synthesis in place of a nucleotide 
residue to insert a texaphyrin in an internal linkage. The 
monoconjugate may then be further coupled to nucleotides 
to produce a texaphyrin-DNA conjugate having the texa 
phyrin in an internal linkage to the oligonucleotide. 
Additionally, phosphonate or phosphodiester derivatives of 
texaphyrin may be utilized to form similar internal, 3', or 5' 
linkages by the phosphonate or triester methods, respec 
tively. 
Oligonucleotide analog conjugates may be coupled to 
texaphyrins in a similar manner as herein described. In 
particular, phosphorothioates. 2'-O-methylated 
ribonucleotides, or other nucleic acid analogs such as methyl 
phosphonate derivatives are preferred due to the enhanced 
stability the derivatization provides towards nucleases in 
vivo. A texaphyrin-oligonucleotide conjugate of a deriva 
tized RNA such as a 2'-O-methyl RNA analog may provide 
stability against self-cleavage. RNA is hydrolyzed by texa 
phyrin complexed with Lu; however, the 2'-O-Me RNA 
lacks a 2'-OH and, therefore, is stable to hydrolysis. 
Therefore, an RNA analog oligomer may be more stable 
than a DNA oligomer for the texaphyrin-oligonucleotide 
conjugate. The synthesis of RNA analog-conjugates is the 
same as for texaphyrin-DNA conjugates discussed previ 
ously herein. An RNA-analog conjugate may be comple 
mentary to an antisense or a sense strand of DNA and forms 
a triple helix in the process of binding to a double helix. 
A further method for the synthesis of texaphyrin 
oligonucleotide conjugates is to incorporate nucleotides 
enzymatically. A variety of DNA and RNA polymerases may 
be used, however, the Klenow fragment of DNA polymerase 
I from E. coli and terminal deoxynucleotidyl transferase are 
preferred. Goodchild, J. (1990) provides a general discus 
sion of the enzymatic synthesis of oligonucleotides and is 
incorporated by reference herein. 
EXAMPLE 5 
Radiation Sensitization of a Murine Leukemia Cell 
Line 
This example describes the use of GdT2B2" as a radia 
tion sensitizer to enhance the radiolysis of a mouse L1210 
leukemia cell line. The presence of the metal is not important 
for the radiation sensitization properties of texaphyrins; 
however, the metal contributes stability to the texaphyrin. 
complex. A metal texaphyrin complex with its counterions is 
considered a neutral complex for purposes of this applica 
tion; for example, GdT2B2(OAc) is a neutral complex. A 
metal complex of texaphyrin, such as GdT2B2* has two 
positive charges. When GdT2B2" picks up an electron, it 
becomes a short-lived t-radical cation, GdT2B2". The 
7t-radical cation picks up a proton or rearranges to the 
texaphyrin radical, GdT2B2(H), which has significant 
stability as described below. 
Physical Studies 
The radiation chemistry of Gd-T2B2" was studied by the 












ionizing radiation (100 ns duration at 4 MeV) was injected 
into an aqueous solution of Gd-T2B2" and the subsequent 
reactions were monitored by absorption spectroscopy. The 
solution conditions were varied so as to optimize the radia 
tion chemistry in favor of reaction with hydroxyl radicals or 
hydrated electrons. First, aqueous solution (pH 7) containing 
Gd-T2B2" (1x10M) was saturated with nitrous oxide so 
as to convert the hydrated electrons into a second crop of 
hydroxyl radicals: 
According to absorption spectroscopy there was no obvi 
ous reaction between hydroxyl radicals and Gd-T2B2" 
under these conditions. Second the aqueous solution (pH 7) 
containing Gd-T2B2" (1x10M) was saturated with nitro 
gen after addition of isopropanol (0.1M). In this case, 
hydroxyl radicals formed in the primary radiolysis event 
abstract the tertiary hydrogen atom from isopropanol, form 
ing the acetone ketyl radical: 
This latter species is a powerful reducing agent and, 
consequently, these reaction conditions provide a reducing 
environment. Both the hydrated electron and the acetone 
ketyl radical reduce Gd-T2B2" in a one-electron process. 
The one-electron reduction potential measured by cyclic 
voltametry for Gd-T2B2" was found to be about 0.08 V vs. 
NHE and, therefore... the compound is readily reduced in 
aqueous solution. 
The resultant t-radical cation of Gd-T2B2, Gd-T2B2" 
o, is readily detected from absorption spectral changes, and 
was found to decay over approximately 200 microseconds. 
This reaction does not result in restoration of Gd-T2B2" 
and its rate increases with decreasing pH. On this basis, the 
observed reaction is attributed to protonation of the TI-radical 
cation: 
The protonated radical, Gd-T2B2(H), decays very 
slowly, having a lifetime of about 30 seconds, by complex 
reactions that did not restore the original Gd-T2B2'. The 
lifetime of this radical is not affected by the presence of 
oxygen, 
Additional pulse radiolysis experiments showed that 
Gd-T2B2" was formed by reduction of Gd-T2B2" with 
superoxide ion (O), carbon dioxide TI-radical anion (CO 
), and the carbon-centered radicals formed by hydrogen 
abstraction from ethanol and methanol. Furthermore, it was 
shown that the protonated radical was formed by reaction 
between hydrogen atoms and GdT2B2". 
It is clear, therefore, that under radiolytic conditions all 
the reducing equivalents can be utilized to reduce 
Gd-T2B2" to Gd-T2B2(H), regardless of the reaction 
conditions. 
Experimental Conditions. For cytotoxicity studies, the 
radiation source was a Phillips 50 KVP constant potential 
X-ray generator, model 120.102.1 equipped with a Machlett 
OEG60 X-ray tube. Dosimetry was made with the Friecke 
dosimeter. This system delivers 110 rads per minute into a 
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target area of about 2 cm diameter. Samples were contained 
in petri dishes mounted into a 12 well tray. Three unirradi 
ated dishes and 3 dishes containing cells without GdT2B2' 
served as control experiments. Six dishes containing cells 
and GdT2B2" were exposed to radiation for a predeter 
mined period. A mechanical arm moved the tray after each 
exposure. After radiolysis, cells were incubated for 24 hours 
and cell viability was established by both methyl red con 
centration and trypan blue exclusion methods using conven 
tional cell counting techniques. All experiments were con 
ducted with log phase cells (5x10 cells per mL). Mouse 
leukemia L1210 cells were maintained in RPMI 1640 cell 
culture medium. 
A stock solution of GdT2B2" (1 mM) was prepared in 
purified water and small aliquots were added to cell suspen 
sions (5x10 cell per mL). The mixture was incubated for 1 
hour at 37° C. before being isolated, washed, and resus 
pended in nutrient solution. In most cases, the concentration 
of GdT2B22+ was 80 M as measured by absorption spec 
troscopy. 
Radiation-induced cleavage of intracellular DNA (or 
RNA) was measured by alkaline elution chromatography. 
Polyvinylchloride filters (pore size 2 pm) were used. 
Samples were exposed to a total of 20 Gy radiation. 
Results. Pulse radiolysis experiments carried out with 
GdT2B2" in aqueous isopropanol are demonstrated in FIG. 
4, 5A and 5B.FIG. 4 demonstrates GdT2B2" t-radical 
cation formation. FIG. 5A demonstrates the ?t-radical cation 
decay in an oxygen free solution and in 5B, decay in the 
presence of O. The data indicate the remarkable stability of 
the GdT2B2 ?t-radical cation and demonstrate that 
GdT2B2" does not pass its electrons to oxygen, nor is it 
affected by the presence of oxygen. The data suggest the 
following intermediate radiolysis products for GdT2B2": 
TABLE 3 
Pulse Radiolysis in Aqueous Isopropanol 
Products 
The GdT2B2" t-radical cation has a half life of less than 
2 milliseconds. It picks up a proton or rearranges to the 
texaphyrin radical, GdT2B2(H), which has significant 
stability and a relatively long half life of about 30 seconds. 
Data in FIG. 6 present the rate constant for the reaction of 
the GdT2B2(H)" radical with cytosine, one of the four 
nucleotide bases of DNA and RNA. It appears that GdT2B2 
(H)' formed a covalent bond with cytosine, this reaction 












Texaphyrin, therefore, has three advantageous properties 
for use as a radiation sensitizer: 
i) The low redox potential of texaphyrin causes hydrated 
electrons to flow to texaphyrin allowing OH to cause 
damage. 
ii) The texaphyrin radical is relatively stable. yet reacts 
readily to modify neighboring molecules covalently. 
iii) Texaphyrin may be particularly effective for treating 
the hypoxic areas of solid neoplasms because of intrin 
sic biolocalization and its indifference to the presence 
or absence of O. It may "replace” oxygen as a redox 
cycle. 
FIG. 7 presents data from an experiment in which mouse 
L1210 cells were exposed to 20 M GdT2B2" and radia 
tion. The control curve represents cell kill in the absence of 
GdT2B2", the curve labeled GdTXP represents cell kill in 
the presence of GdT2B2". A sensitizer enhancement ratio 
(SER) is the ratio of the dose needed to kill 95% of the cells 
without GdT2B2" divided by the dose needed to kill 95% 
of the cells with GdT2B2'. If the sensitizer had no effect, 
the ratio would be 1.0; a very effective sensitizer would have 
a ratio of 3.0. The data of FIG. 7 indicate that at 20 M. 
GdT2B2* has an SER of 1.62. (An SER above 1.5 is 
clinically significant). Two further methods for measuring 
SER are the following: i) The slopes are compared where the 
curve is linear; SER is the ratio of the slope of the compound 
to the slope of the control, or ii) At a particular dose that is 
useful or clinically important, the ratio of number (or %) of 
cells killed in the control is compared to the number (or %) 
of cells killed by the compound. 
The SER increases with increasing concentrations of 
GdT2B2" as indicated in FIG.8. For example, at 80 M. 
the SER is greater than 2.2, indicating that the highest 
physiologically tolerable level of GdT2B2" is desirable for 
radiosensitization purposes. 
Total nucleic acid samples obtained from L1210 cells 
exposed to a total of 20 Gray radiation and varying levels of 
GdT2B2" were passed through a size selection filter (one 
Gray is a unit of absorbed radiation dose equal to 100 rads). 
The data of FIG. 9 indicate that no nucleic acid passed 
through the filter in the absence of GdT2B2* and that in the 
presence of GdT2B2", nucleic acid was cleaved into frag 
ments that passed through the filter. A larger amount of 
fragments was produced with higher levels of GdT2B2" 
exposure. Clearly, nucleic acid strand scission occurs as a 
result of radiation in the presence of GdT2B2". It is 
probable that the hydroxyl radical is responsible for the 
strand scission. 
The radiosensitization properties of the texaphyrins 
described herein may allow reduced doses of radiation to be 
effective in treatment of an individual. Therefore, radiation 
side effects such as nausea and damage to normal cells may 
be lessened when treatment includes the use of texaphyrins 
of the present invention. Expected dose levels for an indi 
vidual may range from 2-20 mol/kg administered in mul 
tiple doses (e.g. before each fraction of radiation). 
This radiation sensitization property of texaphyrins is 
independent of the inserted metal and is a function of the 
texaphyrin ligand only (i.e. Gd(III) ion is not reduced in this 
process). In vitro and in vivo studies on the gadolinium 
texaphyrin complexes also suggest their potential to enhance 
radiation damage, and since this enhancement is unaffected 
by the presence of oxygen, texaphyrins have the potential to 
increase damage in both oxic and hypoxic tumor cells. 
EXAMPLE 6 
Radiation Sensitization of a Human Carcinoma Cell 
Line 
This example-describes the use of three texaphyrins 




enhance the radiolysis of a human HT-29 colonic adenocar 
cinoma cell line in vitro. 
HT-29 cells maintained in RMPI 1680 nutrient medium 
were incubated with various concentrations of either 
GdT2B2", GdT2BET." or LuT2BET* texaphyrin for 24 
hr at 37° C. After incubation, the cells were harvested, 
washed, and resuspended in nutrient medium. Aliquots of 
cell suspensions (5 mL, 5x10 cells per mL) were placed on 
sterilized petri dishes and exposed to radiolysis for varying 
times. The radiation dose was calibrated by Fricke dosim 
etry. After radiolysis, the cells were incubated at 37° C. for 
7 days, after which cell viability was assessed by the trypan 
blue exclusion method. Results were expressed in terms of 
logarithm of the survival fraction relative to non-irradiated 
cells. The controls were carried out with cells not exposed to 
the texaphyrin but irradiated under identical conditions. 
The results for the compounds at 20 IM concentration are 
presented in FIG. 10A, and show that, in the presence of 
each of the texaphyrins (GdT2B2". A; GdT2BET. 4; and 
LuT2BET, ), enhanced cell kill resulted. 
As was true for GdT2B2", the sensitizer enhancement 
ratio (SER) increased with increasing concentrations of each 
of GdT2BET and LuT2BET. as illustrated in Table 4 
below and in FIG. 10B. F.G. 10B also shows cell kill in the 
absence (a) and presence of GdT2BET''' at three concen 
trations (b. 10 M; c. 20 M; d. 40 iM). 
TABLE 4 
Sensitization of HT-29 Cells 
Sensitizer Concentration (M) SER 












In vitro studies performed to determine the SERs for 20 
iM GdT2B2" using various human (HT29) and mouse 
(L1210. VA13, and RF-1) cell lines indicate significant 
radiation sensitization (SERs of 1.92, 1.62. 1.52, and 1.05. 
respectively). Of special note is the SER of 1.92 since this 
suggests that GdT2B2" provides significant radiation sen 
sitization in a human cell line, the human colon carcinoma 
ce line HT29. 
A comparison of the T2B2 gadolinium complex and the 
T2BET gadolinium complex provided comparable SER 
results in HT29 cells at all measured concentrations. The 
comparable radiation sensitization of HT29 cells at 20 iM 
for T2B2 (SER=1.92) and T2BET (SER=2.08) are shown in 
Table 4. Based on these results, the two compounds are 
considered comparable radiation sensitization agents. In 
addition, the radiation sensitization following exposure of 
HT29 cells to 10, 20, and 40M of T2BET (Table 4) shows 
significant radiation sensitization with T2BET (SERs=1.59, 
2.08, and 2.45, respectively). 
These experiments indicate that gadolinium texaphyrin 
complexes are very easily reduced under pulse radiolysis 
conditions. This process is not dependent on oxygen. The 












covalent cytosine bonds and perhaps intracellular DNA. In 
vitro studies using human and mouse cell lines indicate 
significant radiosensitization. This radiosensitization is not 
dependent on oxygen or on cell replication since incorpo 
ration into DNA is not involved in the mechanism of 
texaphyrin-induced radiosensitization. 
EXAMPLE 7 
Radiation Sensitization. In Vivo 
The present example provides data demonstrating the in 
vivo radiation sensitizer effect of texaphyrin T2BET. 
A donor mouse bearing an SMT6 tumor was euthanized 
and the tumor was removed from the leg under aseptic 
conditions. The viable cell number was microscopically 
estimated and then 4-6 million cells were injected into a leg 
of a recipient tumor-free mouse while under anesthesia. 
Tumors in the recipient mice underwent a 4-7 day growth 
phase, dependent on the growth rate of the cells, before 
radiation treatment. 
On the day of radiation treatment, mice with tumors of 
approximately equal size were selected. Gadolinium texa 
phyrin GdT2BET." (2 mol/mL) was administered intrave 
nously by injection in the tail vein. Mice were treated with 
radiation 2 or 5 hours later. A 250 KV Phillips X-ray 
machine and a special mouse legjig, with a lead shield, were 
used. The mouse was positioned prone inside a jig in such 
a way that only the right leg, with the tumor, was exposed 
to the X-ray. A single dose of 10, 20, 30, 40 or 50 Gray of 
radiation was administered. Six studies were run, averaging 
4 test animals in each control and dosage group. Mortality 
and disease-free survival data were acquired as well as 
periodic measurements of tumor size for up to 75 days 
following radiation therapy. Kaplan-Meier survival curves 
were plotted and p-values were determined by log rank 
analyses of the curves. 
The experiments demonstrated that GdT2BET injection 
plus radiation improved the therapeutic results in all groups 
evaluated in comparison to the controls. In comparison to 
animals that received only radiation, statistical significance 
was only achieved in animals receiving a radiation dose of 
30 Gray. Log rank analyses of the Kaplan-Meier survival 
curves for 10 Gray (p=0.86) and 20 Gray (p=0.50) animals 
(FIG. 11A-11B) are not much different with and without 
GdT2BET.", but the curves diverge for the 30 Gray 
(p=0.03) animals (FIG. 11C-11D). The curves for 40 
(p=0.60) and 50 Gray (p=0.97) do not demonstrate any 
statistically significant difference in treatment. The studies 
that did not show statistical significance. however, are based 
on fewer numbers of animals. 
The data indicate that the 30 Gray dose of radiation 
produces partial control of tumor growth, which could be 
potentiated by T2BET injection (FIG. 11C-11D). Lower 
doses of radiation are not adequate to observe a benefit from 
the administration of T2BET injection. At higher doses. 
tumor response is very good in both control (radiation alone) 
and T2BET injection plus radiation-treated animals, making 
it difficult to observe benefit of treatment with the sensitizer. 
Efficacy of T2BET injection as a radiation sensitizer was 
also demonstrated in these studies by plotting survival and 
cancer-free (primary site) survival (FIG. 11A-11D). Tumor 
growth delay was also greater in animals receiving both 
radiation (animals dosed at 30, 40, and 50 Gray) and the 
T2BET injected radiation sensitizer. 
EXAMPLE 8 
Radiation Sensitization Combined with Localization 
and/or Photodynamic Therapy 
This example describes the use of texaphyrins in com 
bined methods of localization and radiation sensitization, 
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and radiation sensitization combined with PDT for destruc 
tion of neoplastic tissue and atheroma. A method of radiation 
sensitization is combination with localization by reference to 
a detectable texaphyrin is as follows. A detectable texaphy 
rin is administered to a host harboring a neoplasm or 
atheroma. Localization sites in the host are determined by 
reference to the texaphyrin. Localization means may be 
fluorescent spectroscopy, especially when the texaphyrin is 
non-metallated or is complexed with a diamagnetic metal; 
magnetic resonance imaging when the texaphyrin contains a 
metal that is paramagnetic; gamma camera body scanning 
when the metal is gamma emitting; or by using diagnostic 
x-rays, especially mono-or polychromatic X-rays with 
energy around the K electrons of metals bound to texaphy 
rin. Gamma emitting metals for radioimmunodiagnostics are 
described in U.S. Pat. No. 5.252.720, incorporated by ref 
erence herein. A preferred gamma emitting metal is 'In 
(III). Texaphyrin-paramagnetic metal complexes would 
afford the advantage of visualization of the tumor by MRI. 
Preferred paramagnetic metals are Gd(III). Fe(III), or 
Mn(II), and a most preferred paramagnetic metal is gado 
linium. The opportunity to combine imaging with radio 
therapy is appealing since definition of treatment fields is an 
important component of radiotherapy delivery. In vivo 
experiments with GdT2BET injection in mice and rabbits 
have demonstrated that GdT2BET''' injection produces 
good contrast enhancement of tumors with doses as low as 
5 pmol/kg and biodistribution studies with 'C-labeled 
GdT2BET' have shown good differentiation between 
tumor and surrounding tissue. 
Although GdT2BET' has light-absorbing capabilities in 
the visible portion of its electronic spectra (major absorption 
peaks at about 415, 473, and 739 nanometers), it is not a 
photosensitizer because the Gd unpaired electrons immedi 
ately quench the excited state of the organic ligand induced 
by light. Free base texaphyrins or texaphyrins complexed 
with diamagnetic metals are photosensitive and generate 
singlet oxygen upon photoirradiation. 
A method of radiation sensitization in combination with 
photodynamic therapy is as follows. A texaphyrin is admin 
istered to a host harboring benign or malignant neoplasm 
cells or atheroma. The texaphyrin exhibits radiosensitization 
properties and selective biolocalization in benign or malig 
nant neoplasm cells or atheromatous plaque relative to 
surrounding tissue. Localization sites in the host are deter 
mined by reference to the texaphyrin using, for example, 
magnetic resonance imaging when a paramagnetic metal 
complex of texaphyrin is administered, fluorescence when a 
free-base texaphyrin or a texaphyrin diamagnetic metal 
complex is administered, or gamma camera (or SPECT. 
single photon emission computed tomography) body scan 
ning when a gamma-emitting metal is complexed within the 
administered texaphyrin. A preferred paramagnetic metal is 
Gd(III). A preferred diamagnetic metal is Lu(III). In(III) or 
LA(III) A preferred gamma-emitting metal is 'InCIII) 
The inherent radiosensitization properties of the texaphy 
rins allow electromagnetic radiation to be more effective and 
selective when administered in the vicinity of the texaphy 
rin. Lower doses of radiation may therefore be used. The 
radiation may be from an external source or may be from an 
internal source, such as a radioactive metal bound to a 
texaphyrin. Examples of a radioactive metal include 'Gd, 
'In, or Y. Alternatively, a second texaphyrin metal com 
plex having essentially identical biolocalization property 
and exhibiting the ability to generate singlet oxygen upon 
exposure to light is administered. The second texaphyrin 












or malignant neoplasm cells or atheroma, possibly using 
fiber optics or laser, to cause neoplasm tissue destruction or 
atheromatous plaque destruction from the singlet oxygen 
produced. The metal in the second texaphyrin metal com 
plex is a diamagnetic metal, preferably La(III), Lu(III) or 
In(III). 
A further embodiment is the use of a texaphyrin radiation 
sensitizer and a photosensitive texaphyrin for treatment. 
This molecule may be a single texaphyrin diamagnetic metal 
complex, since the metal is not important for radiosensiti 
zation. A synergistic killing of cells may then be achieved by 
the use of light for photodynamic therapy followed by or in 
combination with electromagnetic radiation. An alternative 
embodiment is a synergistic killing due to an intrinsic 
radiochelated texaphyrin and externally applied radiation. In 
vitro uses of the method of radiosensitization and radiation 
therapy include sterilizations, and in the treatment of bone 
marrow, transfused blood or transplanted organs. 
Texaphyrin-metal complexes will be chosen which them 
selves show a high intrinsic biolocalization selectivity for 
neoplasms, neoplastic tissues or atheroma. For example, the 
B2T2 and the T2BET texaphyrins demonstrate in vivo 
affinity for tissue high in lipid content, atheroma, the liver. 
kidneys and neoplasms. 
The texaphyrin complexes are good candidates for such 
biomedical radiation sensitizers and photosensitizers. They 
"soak up' electrons in an irradiated area allowing hydroxyl 
radicals to cause radiation damage, and the texaphyrin 
radicals react covalently with neighboring molecules caus 
ing further radiation damage. They are easily available, have 
low intrinsic cytotoxicity, long wavelength absorption, gen 
erate singlet oxygen, are soluble in physiological 
environments. have the ability to be conjugated to site 
specific transport molecules, have quick elimination. are 
stable and are easily subject to synthetic modification. 
Significant advantages to using texaphyrins for imaging and 
destruction of cells are: 
i) one texaphyrin can be used for both functions; 
ii) texaphyrins possess inherent selective biolocalization 
and have the potential for derivatization to enhance that 
localization; 
iii) since texaphyrins are radiation sensitizers, radiation is 
more effective and lower doses of radiation may be 
used, therefore fewer side effects are experienced; and 
iv) a metal complex is not necessary for radiosensitiza 
tion. 
The present invention provides a method to "see" and 
"kill” particular cells with a single agent having biolo 
calization selectivity and radiation-enhancing proper 
ties. 
The following references are incorporated in pertinent 
part by reference herein for the reasons cited below. 
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It is understood that the examples and embodiments 
described herein are for illustrative purposes only and that 
various modifications in light thereof will be suggested to 
persons skilled in the art and are to be included within the 
spirit and purview of this application and scope of the 
appended claims. 
We claim: 




M is a divalent metal cation or a trivalent metal cation; 
and 
N is 0,1 or 2. 
2. A texaphyrin according to claim 1 wherein M is a 
divalent metal cation selected from the group consisting of 
Ca(II), Mn(II), Co(I), Ni(II), Zn(II), CdCII), Hg(II), Fe(II), 
Sm(II) and UO(II) or a trivalent metal cation selected from 
the group consisting of Mn(III), Co(III), Ni(III), Fe(III), 
Ho(III), Ce(III), Y(III). In(III). Pr(III). NdCIII), Sm(III). 
Eu(III), Gd(III), Tb(III). Dy(III), Er(III). TmIII), Yb(III), 
Lu(II). La(III) and U(III). 
3. A texaphyrin according to claim 1 wherein M is 
selected from the group consisting of Gd(III). Lu(III), 
Eu(III). Dy(III), TbOIII) and Y(III). 
4. The texaphyrin of claim 1 wherein M is Gd(III). 
5. The texaphyrin of claim 1 wherein M is Lu(III). 
6. The texaphyrin of claim 1 wherein M is Eu(III). 
7. The texaphyrin of claim 1 wherein M is Dy(III). 
8. The texaphyrin of claim 1 wherein M is Y(III). 




10. The texaphyrin of the following formula: 
OH 
11. A texaphyrin metal complex associated with from 1 to 
6 apical ligands about the metal center. 
12. A texaphyrin metal complex associated with from 1 to 
6 apical ligands about the metal center, wherein the texa 





13. A texaphyrin metal complex having the formula: 
wherein. M is a divalent or trivalent metal cation; R is 
CHCH or (CH2)CH-OH; and R is O(CH2)CH-OH 
or O(CHCHO)CHCHOCH; and 
wherein, the texaphyrin metal complex is associated with 
from 1 to 6 apical ligands about M. 
14. A texaphyrin metal complex according to claim 13 
wherein M is a lanthanide metal cation. 
15. A texaphyrin metal complex according to claim 13 
wherein M is selected from the group consisting of Gd(III), 
Lu(III), Y(III), Eu(III), Dy(III) and Tb(III). 
16. A texaphyrin metal complex according to claim 13 
wherein the apical ligands are selected from the group 
consisting of acetate, chloride, nitrate, hydroxide, water and 
methanol. 
17. A texaphyrin metal complex according to claim 12 
wherein the apical ligands are not readily dissociable from 
the metal complex. 
18. A texaphyrin metal complex according to claim 13 
wherein the apical ligands are not readily dissociable from 
the metal complex. 







wherein, the texaphyrin metal complex is associated with 2 
apical ligands about the Lu metal center. 
20. A texaphyrin metal complex according to claim 19 
wherein the apical ligands are selected from the group 
consisting of acetate, chloride, nitrate, hydroxide, water and 
methanol. 
21. A texaphyrin metal complex according to claim 19 
wherein the apical ligands are not readily dissociable from 
the metal complex. 
22. The texaphyrin metal complex according to claim. 19 
wherein the apical ligands are acetate apical ligands and are 
not readily dissociable from the metal complex. 




wherein, the texaphyrin metal complex is associated with 2 wherein the apical ligands are not readily dissociable from 
apical ligands about the Gd metal center. the metal complex. 
24. A texaphyrin metal complex according to claim 23 26. The texaphyrin metal complex according to claim 23 
wherein the apical ligands are selected from the group wherein the apical ligands are acetate apical ligands and are 
consisting of acetate, chloride, nitrate. hydroxide, water or not readily dissociable from the metal complex. 
methanol. 
25. A texaphyrin metal complex according to claim 23 35 ck k xk k : 
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